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Dr. FA Mann, Dissertation Supervisor 
 
ABSTRACT 
 
Objective:  To determine the temporal change in lipid particle size in veterinary 
parenteral nutrition (PN) admixtures kept at room temperature (23°C) versus admixtures 
filtered, refrigerated, and agitated.   
Procedure:  Fifteen 2 L bags of PN admixture containing 50% dextrose (525 mL), 20% 
lipid emulsion (453 mL), 8.5% amino acids/electrolyte solution (840 mL) and vitamin B 
complex (5 mL) were delivered through an intravenous pump (16 mL/hr) for 96 hours. 
Group 1 (n=3) was static, Group 2 (n=3) was continuously agitated, Group 3 (n=3) was 
agitated for 5 minutes every 4 hours, Group 4 (n=3) was static at 4°C, and Group 5 (n=3) 
was filtered (5 μm pore).  After 96 hours, two 10 mL samples of PN (n=3) were cultured 
(bacterial).  Samples (1.0 mL) were collected at 0, 24, 48, 72, and 96 hours and examined 
with transmission electron microscopy.  Computer software (Adobe Photoshop & Fovea 
Pro) provided lipid particle diameters.  Significance of time effects on size distribution 
was evaluated with Repeated Measures ANOVA.     
Results:  There was no significant difference in lipid particulate size among or within 
groups over time (p≤0.05).  Group 2 separated into a visible oil layer by 72 hours.  There 
was no bacterial growth (aerobic or anaerobic).   
Conclusion:  Lipid particulate size is stable in this veterinary PN admixture for more 
than 48 hours at 23°C.  Manipulations of PN are unnecessary to prolong lipid particle 
stability; continuous agitation may hasten lipid breakdown.   
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Chapter I. Veterinary parenteral nutrition: an introduction 
 
Part 1. Historical focus 
All animals begin their lives in utero, receiving nourishment entirely by vein…. 
Stanley Dudrick, MD1 
…[parenteral nutrition is] the intravenous administration of sufficient nutrients 
above the basal requirements to achieve tissue synthesis, positive nitrogen 
balance, and anabolism. 
Flack JL, et al.2 
 The above two statements embody the conundrum that is parenteral nutrition 
(PN).  On one hand the goal is very clear: to provide nutrients to a patient and allow the 
patient’s metabolism to shift from a catabolic state to one where healing and tissue 
regrowth is possible.  However, as with so many things in life, trying to simulate the 
human body and the intravenous feeding provided from mother to child is a difficult, if 
not impossible, goal to attain.  Physicians working in pursuit of this goal have developed 
a complex field in human medicine that is constantly re-defining and changing the way 
nutrition is administered to patients.   
 The very first experiments with parenteral nutrition date from the 1600s when 
physicians used sharpened quills to administer milk and wine into the veins of dogs.3,4 As 
expected, such experimentation did not yield favorable outcomes and the concept of 
intravenous nutrition was placed on hold for many years.  Then, in the 1800s when 
cholera became a devastating cause of death amongst humans, a major breakthrough 
caused intravenous therapy to re-enter the medical consciousness.  That breakthrough 
was the life-saving and groundbreaking use of intravenous saline solutions which made 
physicians acutely aware that administering medications intravenously was a viable 
treatment option.4 
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 The next hurdle in the development of PN was to obtain the nutritional 
components in a form that could be utilized intravenously.  The three basic building 
blocks of modern-day PN are dextrose and lipid sources to provide for the patient’s 
caloric needs and amino acids to supply the body with anabolic compounds for protein 
synthesis.  To this end, the first innovation came in the form of intravenous dextrose 
solutions.4 The first experimentation with intravenous dextrose solutions was in 1915; 
this early work was expanded in the 1930s and 1940s to include both continuous 
infusions of dextrose and the administration of dextrose through the superior vena cava 
rather than a peripheral vein.  The successful use of a central vein allowed researchers to 
deliver highly concentrated dextrose solutions (greater than 10%); previously, such 
hypertonic solutions could not be given through peripheral veins without causing damage 
to the vascular endothelium.4 
 On the heels of the creation of intravenous dextrose solutions came the 
development of protein hydrolysates in the 1930s and 1940s which provided protein in a 
form that could be administered intravenously.3 These protein infusates became modified 
into our modern amino acid solutions in the 1970s.4 All that was left then was 
development of another concentrated calorie source that could be utilized with dextrose 
to provide for the patient’s caloric requirements.  Several compounds were 
unsuccessfully tried including alcohol-containing solutions and various lipid solutions.3,4 
Finally in the 1960s, soybean-containing lipid emulsions were developed which fulfilled 
the need for another calorie source, breaking down the final barrier in the creation of the 
building blocks of modern parenteral nutrition.3,4 
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 From these beginnings, it seemed that the development of total parenteral 
nutrition (TPN) designed to provide for all calorie needs of a patient could not be far 
away.  However, in the 1960s, there were still several key hindrances to creating and 
using PN in human patients.1 The first was the medical community’s dogmatic conviction 
that nutrition had to be administered through a peripheral vein.2 Phlebitis and venous 
thrombosis were common sequelae to the peripheral administration of intravenous 
solutions and patients uniformly found the process uncomfortable.  Additionally, the 
usage of peripheral veins limited the concentration of dextrose that could be 
administered.  A second large hurdle was the fact that the patient could not be 
administered more than 2500 to 3500 mL of liquid volume per day.1 This severely 
restricted the volume of calories and protein that could be given to a patient and seemed 
to make it impossible to attain full caloric supplementation.   
 The remaining seemingly insurmountable impediments were all centered around 
the fact that the creation of protein, lipid, and dextrose sources to use intravenously were 
in their infancy and not as widely available or available in as many forms as needed.1 
These obstacles frustrated early researchers and physicians until the 1980s.  At that point, 
technology had caught up with the dream of researchers and modern day lipid emulsions, 
dextrose solutions, and amino acid solutions were finally available and successfully 
combined into nutritional admixtures.   
 Fittingly, the first actual experimentation with TPN solutions was performed in 
beagles by Dr. Stanley Dudrick and his team over the course of several experiments in 
the 1960s.  The dogs were given single solutions of TPN with all required amino acids, 
dextrose, electrolytes, lipids, vitamins, and minerals combined into a single solution.3,4,5 
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In so doing, much trial and error was required to both ensure that the various electrolytes 
did not precipitate with each other (especially calcium and phosphorus) and that the 
admixture was mixed aseptically.  Additionally, this landmark work required the 
development of central venous catheterization in the dogs in order to administer the 
nutritional admixtures.1 That the researchers were able to overcome every obstacle in 
their path was demonstrated by the results of their work: puppies fed parenterally for 72 
to 256 days outweighed their orally-fed littermates and matched their littermates in 
skeletal growth, development, and activity levels.6   
 From here, the jump from dogs to humans came much faster than expected.  In a 
bold move after seeing these positive findings in the beagles, Dudrick and his peers 
almost immediately began to use a modified version of the puppy feeding formulation in 
humans in 1966.3,7  Six severely malnourished humans with diseases ranging from 
regional enteritis to bowel obstructions and pancreatitis were successfully fed for six 
days.  During that time, the viability of TPN as a treatment modality seemed clear; all six 
patients displayed positive nitrogen balance, weight gain, normal wound healing, and 
increased strength and physical and mental activity levels, leading to their successful 
discharge from the hospital.  In 1967, TPN was used for the first time in a human infant 
who was born with near total small bowel atresia leading to a duodenal-ileal anastomosis.  
The baby was fed successfully for a total of 22 months using TPN before her eventual 
death.1,8  
 
 Ironically, from these ostentatious beginnings in human medicine where 
experimentation on beagles played such a key role in the development of parenteral 
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nutrition, veterinary medicine did not seek to embrace PN until a publication in 1977.9 In 
that study, researchers fed 10 adult mixed breed dogs intravenously for three weeks total 
using a similar technique as employed in the very first beagle studies.  The dogs were fed 
a total of 132 kcal/kg/day through central venous catheters using a combination of protein 
hydrolysate solution, 50% dextrose solution, and an electrolyte solution containing 
sodium, chloride, and potassium.  All canine patients maintained their weights and 
activity levels throughout the feeding period, proving again the viability of providing 
nutrients intravenously to dogs for long periods of time.  In fact, the only negative 
findings in the study were thrombus formation in the jugular veins of five dogs and an 
overall great difficulty in keeping continous delivery of the nutritional admixture to such 
non-debilitated patients.   
 In contrast to human medicine’s eager acceptance of parenteral nutrition, the 
veterinary literature of the time was very quiet aside from scattered case reports of using 
PN in solitary veterinary patients until a 1989 report where TPN was administered to 
clinically normal cats over a two week period.10 This study attempted to replicate the 
canine study to determine the viability of TPN administration to cats.  A total of seven 
clinically normal cats were given TPN containing dextrose, amino acids, soybean oil lipid 
emulsion, electrolytes, and vitamins.  Overall, the conclusions of the study were that the 
patients were successfully fed via TPN.   However, three cats inadvertently given more 
than their calculated caloric content had some negative side effects including weight gain, 
vomiting, depression, and oral ulceration.  All cats given TPN also developed reversible 
normocytic normochromic anemia, hepatocellular swelling and vacuolization, and small 
intestinal villous atrophy.  The hepatic changes were attributed to taurine deficiency in 
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the PN rather than the PN itself, leading to the conclusion that cats, like dogs, could be 
maintained for a reasonable duration of time on PN without significant permanent 
changes.     
 
Part 2. Genesis of the thesis research  
 Moving forward into the 21st century, total parenteral nutrition has become a well-
recognized feeding modality in companion animal medicine.  However, despite its 
widespread use, there is very little information currently published regarding the use of 
PN admixtures in the veterinary literature.  Unlike many other areas of human and 
veterinary medicine where much is similar between the species, allowing for significant 
extrapolation and translation from human to veterinary medicine, PN usage diverges 
between humans and animals.   
To understand the basics of the current usage of PN in human and animal 
medicine, it is important to understand that there are two concerns when PN admixtures 
are compounded – nutrition and safety.  It is well recognized that dextrose solutions have 
a long shelf life in PN admixtures and do not suffer from degradation of their nutritional 
value over time.   Precautions such as covering amino acid solutions to protect them from 
light and care taken when preparing the admixtures have also virtually eliminated 
concerns about amino acid breakdown. 11 Multivitamins are widely known to be 
nutritionally the most labile of the PN components.11,12 This is typically not a concern in 
veterinary medicine due to the relatively short duration that our patients are provided PN 
(days to weeks rather than months to years); there is simply not enough time for the 
average patient to develop a vitamin deficiency secondary to breakdown of the vitamin 
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components of PN.  Additionally, care taken to cover administration bags to protect them 
from light as well as using specialized PN admixture bags helps to reduce chances of 
vitamin degradation due to light exposure as well as minimize the binding of vitamin 
components to the plastic PN bag (and therefore the loss of those vitamins from the 
admixture).12   
The majority of safety concerns about PN admixtures have been eliminated by 
appropriate pharmacological preparation of solutions.  The early concerns about bacterial 
and fungal growth in the PN solutions have proved to be unfounded because the high 
osmolarity and relatively low pH of PN solutions administered through central venous 
lines makes it very difficult for those organisms to survive.12,13  The Maillard reaction (the 
decomposition of carbohydrates by amino acids such as glycine) has virtually been 
eliminated when these components are compounded by a pharmacist.11,12 The 
precipitation of calcium and phosphorus has also been greatly reduced by proper 
pharmacologic preparation -- the components are added at different times during the 
compounding procedure to minimize chance of precipitation. 11,12 
However, the addition of lipids to PN admixtures still raises actual safety 
concerns regarding the duration of stability of the resulting solution.  Lipid molecules 
have a tendency to coalesce into larger particles.  The initial stages of lipid particle 
degradation include creaming, where lipid particle rise to the surface of an emulsion, and 
flocculation, where individual lipid particles become associated with each other into 
groupings.  Both these early stages of degradation can be reversed by agitation of the 
solution.11 However, once the particles coalesce into larger particles, the degradation is 
irreversible.  In response to concerns about coalescence of lipid particles, the Food and 
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Drug Administration (FDA) recommends that lipid-containing admixtures be 
administered for no more than 24 hours.14 This recommendation has been adopted by the 
University of Missouri-Columbia Veterinary Medical Teaching Hospital (VMTH) and 
other veterinary institutions for all lipid-containing PN admixtures.   
The normal size of chylomicrons in the bloodstream is 0.4 to 1.0 µm.  A lipid-
containing solution is considered unsuitable for use when coalescence of lipids leads to 
particles larger than 5.0 μm in size and these particles make up greater than 0.4% of a 
solution; such an abundance of large particles puts an animal receiving PN at risk for 
lipid-induced pulmonary emboli.11,13, 15,16  The early work that led to the determination of 
the upper limit of “safe” lipid particle size was performed in 1965.17  The investigators 
found that hypotension and dyspnea were apparent in dogs when fat particles greater than 
6 µm were given intravenously.  The basis of the 0.4% cut-off for the quantity of large 
lipid particles comes from studies in 1969 and 1986 that determined clearance of lipid 
particles from the bloodstream by various organs.  Approximately 0.4% of lipids injected 
into an animal were cleared by the lung.18,19 
There have been several investigations evaluating the best technique for the direct 
assessment and measurement of lipid particles in solutions.  The most accepted published 
techniques are light obscuration particle measurement, photon correlation spectroscopy 
(PCS), and a transmission electron microscope technique (TEM).20-22  It has been 
concluded that TEM and PCS are roughly equivalently accurate techniques and superior 
to light obscuration particle measurement for particle size enumeration.22  In comparing 
PCS to TEM, particles smaller than 100 nm are easy to identify with TEM and particles 
smaller than 120-150 nm may be difficult to detect using PCS.23  A recognized potential 
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limitation of all particle-sizing techniques is that the sample sizes examined are very 
small and therefore may not be representative of the entire admixture.24  Nevertheless, 
TEM imaging is considered an accurate and reliable means for identifying particle size in 
lipid emulsions.   
As indicated above, stability studies of PN admixtures kept at room temperature 
for more than 24 hours are very few in number, largely due to the adherence of most 
institutions to the FDA recommendations, which precludes the need for such studies.  
However, the degradation of lipid admixtures is known to be time and temperature 
dependent.14   Multiple published studies have determined convincingly that lipid 
admixtures can be safely stored at refrigeration temperatures for days to weeks prior to 
their administration to a patient over 24 hours.25-29   The few studies that have examined 
lipid particle size when admixtures were kept at room temperature for more than 24 hours 
employed a variety of techniques to detect lipid particle size from visual inspection to 
light microscopy to Coulter counting.16,30,31,32  Within the limitation of the techniques 
employed, these studies suggested that lipid containing admixtures were stable for greater 
than 24 hours.   
It is a simple fact that in veterinary medicine the medical needs of the patient 
must be balanced with the financial ramifications for the client, especially since the 
majority of our veterinary patients are not covered by health insurance.  As such, one of 
the limitations to the use of PN is its cost.  A large portion of the cost of PN is due to the 
special bag in which the PN formulation is stored (33% of the daily cost of PN at the 
VMTH Pharmacy).  If a bag of PN can be used for 48 hours or more, the cost-
effectiveness of administering PN would be enhanced. It would also be more convenient 
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for hospital staff, and result in cost savings for the client, if daily bag changes were not 
necessary.  Additionally, as reported in the human literature, the fewer changes to the PN 
line and handling of the catheter port used to administer PN, the less chance of 
mechanical complications and introduction of catheter-related infections.11,13,33,34 Thus, if 
daily line and bag changes are not necessary, the chances of these complications would 
be reduced.   
  
  Therefore, from these beginnings came the goals of this thesis research.  The first 
goal was a determination -- using electron microscopy -- of the duration of time before 
lipid particles coalescenced into pro-embolic particles at room temperature.  A second 
goal was to determine if manipulations to the PN will prolong the lifespan of admixtures. 
Such manipulations included refrigeration of PN as it was administered, agitation of the 
admixtures to re-suspend the lipid particles in solutions, and filtering to remove any 
particles larger than 5 µm.   
 The overriding goal of the entire project was to determine how to maximize the 
duration that a single bag of PN could be administered to a patient before lipid particle 
destabilization.  This determination would hopefully not only result in savings for the 
client by prolonging the hang-time of a single bag of PN but also limit the frequency that 
PN bags are changed, reducing mechanical and sterility concerns regarding changing the 
PN bags.  The hope was that a more precise determination of the safe hang-time of PN 
bags would be of wide-reaching interest to those veterinarians implementing lipid-
containing PN admixtures in their hospitals, and would potentially standardize care in the 
duration of use of those same PN admixtures.   
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Part 3. From here to there 
 
In studying the history of the human mind one is impressed again and 
again by the fact that the growth of the mind is the widening of the range 
of consciousness, and that each step forward has been a most painful and 
laborious achievement. 
Carl Jung (1875 - 1961)  
 
History is the witness that testifies to the passing of time; it illumines 
reality, vitalizes memory, provides guidance in daily life and brings us 
tidings of antiquity. 
Cicero (106 BC - 43 BC)  
 
 All things begin with the history that is written and then are shaped by current 
events.   The same goes for this project.  As detailed in chapter one, parenteral nutrition 
has grown from a dream into a reality in human and veterinary medicine.  And, as is 
clearly noted in the case of lipid particles and their degradation over time, complete 
understanding of the individual components and the theory of their usage in PN is of 
paramount importance.  This brings us to chapters two and three of this thesis wherein I 
delve deeply into the exact formulation of veterinary parenteral nutrition including the 
reasoning (when known) for both the components in PN and their dosages (chapter two).  
The natural progression from this discussion is a discourse on exactly how to create and 
administer PN to a patient (chapter three).  And then of course chapter four’s content – 
our findings regarding lipid particle sizing in veterinary parenteral nutrition admixtures – 
is presented to the reader as a culmination of all that has gone before it.      
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Chapter II.  A Primer on Parenteral Nutrition Part 1: Uses, Indications, 
and Compounding 
 
As decreased caloric and nutrient intake can complicate the course of both mild and 
serious illness, parenteral nutrition (PN) is an important feeding modality for patients 
who are unable to receive adequate enteral nutrition.  Many pharmacy facilities are 
capable of compounding PN formulations; with proper staff training and patient 
monitoring, PN can potentially be performed in most veterinary practices.   Part I 
provides information on the components of PN formulations as well as criteria for 
rational selection of patients to receive PN.  Part II (chapter III) discusses typical PN 
formulations and addresses the monitoring of patients and potential complications of PN 
administration.   
_____________________________________________________ 
A problem commonly faced in veterinary medicine is maintaining the nutrient and 
caloric requirements of patients who are hyporexic, anorexic, or otherwise unable to 
utilize nutrition enterally.  While it is true that the goal is to discover and resolve the 
underlying condition, allowing the patient to go without food until the condition is 
resolved may contribute to morbidity and prolong therapy.  In most if not all cases, 
supplemental nutrition is beneficial to the patient.   
One potential modality for the administration of nutrition is parenteral nutrition 
(PN).  PN describes intravenous administration of nutritional products35 and has been 
successfully utilized in human medicine since 1966.1 In veterinary medicine, PN has 
become progressively more widely used since the 1990’s although the first published 
veterinary study demonstrating the provision of complete intravenous nutrition to dogs 
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was in 1977.9 Parenteral nutrition may be classified as total parenteral nutrition (TPN) 
and peripheral (or partial) parenteral nutrition (PPN).   
Definitions: 
• Total Parenteral Nutrition 
In human medicine, the strict definition of total parenteral nutrition refers to the 
intravenous provision of the total nutrient needs of the patient.  As practiced in veterinary 
medicine, TPN may not supply all nutrient needs since the specific requirements of our 
critical canine and feline patients have not been as thoroughly investigated as in human 
patients.  As such, it is controversial whether TPN formulations are appropriately 
supplemented with the vitamins, macrominerals, and trace elements required for long-
term nutritional maintenance.36,37 However, veterinary TPN does attempt to supply all the 
energy and protein needs of a patient.  Classically, veterinary TPN is administered 
through a central vein due to the high osmolality of the solution. 
• Peripheral and Partial Parenteral Nutrition 
The abbreviation PPN refers to either partial parenteral nutrition or peripheral 
parenteral nutrition.  PPN solutions are less hyperosmolar than TPN solutions and as such 
are safely administered into peripheral veins.  It is possible to formulate PPN to provide 
all daily energy, protein, vitamin, and mineral requirements – these solutions are referred 
to as peripheral parenteral nutritional solutions because they are supplied through a 
peripheral vein.  However, many times the volume of PPN required per day to meet the 
full energy needs of the patient is excessive because PPN has a greatly reduced 
osmolarity versus TPN.  As such, veterinary PPN is not commonly formulated to fully 
supply either the daily energy or vitamin and mineral requirements but rather seeks to 
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provide a portion of the total energy requirements (commonly 50% of the total daily 
energy requirements).  These solutions therefore provide partial parenteral nutrition.36,37  
(Table 1) 
Feeding patients 
• Metabolic Changes When Food Intake Is Decreased 
 Patients that require nutritional support suffer from either uncomplicated 
starvation or stressed starvation.36,38 Uncomplicated starvation results when an animal is 
deprived of food sources, but the animal is not injured or ill.  To decrease their nutrient 
needs, starving animals (especially dogs) will commonly lower their metabolic rates and 
down-regulate the release of catecholamines and other stress hormones.36 These animals 
have decreased insulin secretion and rely on gluconeogenesis and hepatic glycogenolysis 
to supply glucose to their tissues.  Fatty acids are broken down to provide ketone bodies 
for energy and skeletal muscle, and body proteins are broken down to amino acids that in 
turn are used for gluconeogenesis.  In cases of short-term uncomplicated starvation, 
providing food will reverse the metabolic change, allowing the patient to shift back to a 
normal metabolic rate and begin to use carbohydrates preferentially for energy.  In cases 
of prolonged uncomplicated starvation, there is still a potential for negative side effects to 
ensue when animals are re-introduced to food.   One reported side effect is the refeeding 
syndrome (a syndrome of hypophosphatemia, hypokalemia, and hypomagnesemia 
induced by the introduction of food to an anorexic patient) which is discussed at length in 
chapter III.   
 Stressed starvation occurs when ill or injured animals do not have adequate food 
intake.36,38 Many of these patients have elevated resting metabolic rates and an increase in 
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protein catabolism proportional to the extent of disease.36 The production of 
catecholamines and other stress hormones is upregulated, leading to increased cardiac 
output and systemic vascular resistance, insulin resistance, proliferation of inflammatory 
mediators, and a rapid onset of malnutrition.36  
Feeding patients suffering from stressed starvation is challenging for multiple 
reasons.36,38 These animals have relative insulin resistance and do not utilize exogenous 
carbohydrate sources as efficiently as a non-stressed animal.  It is also important to 
provide them with sources of amino acids to help reduce protein catabolism.  Moreover, 
it is difficult to determine the actual energy requirements for these animals because they 
may have increased resting metabolic rates associated with stress and disease.  However, 
it is equally difficult to determine the exact degree of increase of the metabolic rate.  And, 
as discussed more thoroughly below, the underlying reason for the patient’s stressed state 
can be important in determining how they will respond to supplemental nutrition.   
• Enteral versus Parenteral Nutrition 
When deciding to provide nutritional support to a patient, enteral nutrition (ie. 
orally or through feeding tubes placed directly in the gastrointestinal tract) is preferable 
to parenteral nutrition in patients in which it is tolerable and not contraindicated (Table 2 
and 3).  Enteral nutrition is more physiologic than parenteral nutrition; it has been 
demonstrated that the gastrointestinal tract suffers from atrophic changes when it is not 
utilized.  Histologic examination of samples of the liver and small intestine from normal 
cats before and after two weeks of complete nutritional support by TPN revealed swelling 
and vacuolization of hepatocytes and mild to moderate small intestinal villous atrophy.10 
All changes were reversed three weeks after the animals resumed normal enteral feeding.  
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There is also evidence of decreased muscular contraction of the gall bladder, stomach, 
and duodenum during TPN administration.39 In addition to contributing to gall bladder 
sludging, gut stasis may lead to bacterial overgrowth and predispose the patient to 
bacterial translocation and sepsis.39,40  
Parenteral nutrition should be reserved for patients unable to utilize all or part of 
the gastrointestinal tract to digest and absorb nutrients.  When patients have been in a 
good nutritional status prior to acute illness (ie. the patients were not malnourished prior 
to their current illness), it is possible to delay the start of nutritional supplementation for a 
maximum of five days of decreased or absent nutritional intake, although it is 
encouraged to start sooner.41 It is important to take historical information into account 
when determining the need for nutritional support because many animals may have been 
anorexic or undernourished for one or more days prior to admission to the veterinary 
hospital.  On the other hand, if the patient was already under-nourished prior to its current 
illness, it is important to begin nutritional supplementation immediately, regardless of the 
number of days of complete anorexia.  (Table 4) 
 
Components of Parenteral Nutrition 
Parenteral nutritional solutions are primarily comprised of carbohydrates, amino 
acids, electrolytes, and possibly a lipid substrate.  Some formulations will also include 
vitamins and mineral supplementation.  The carbohydrate source utilized in the majority 
of TPN formulations is 50% dextrose which contributes most of the osmotic pressure of 
the solution.  Peripheral parenteral solutions contain a lesser concentration of dextrose 
(typically 5% dextrose) and thus have a greatly reduced osmolarity.  Most PN solutions 
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also contain synthetic amino acid formulations that may or may not contain electrolytes.  
The lipid component is supplied as a commercial lipid formulation made primarily of 
long-chain triglycerides derived from soybean and/or safflower sources.   
• Carbohydrates in parenteral nutrition 
The goal of using dextrose and lipid-based formulations is to provide non-protein 
energy sources for the patient.  Dextrose is normally a readily utilizable energy source 
that can be transported from the bloodstream directly into the cells through the actions of 
insulin.  Once in the cell, the glucose is readily converted into adenosine triphosphate 
(ATP) through the actions of the Kreb’s cycle.   
However, in practice, there are limitations to dextrose therapy.41 The proportion 
of dextrose in a PN admixture must be limited to prevent excessive osmolarity.  Dextrose 
in excessive quantities may lead to thrombophlebitis, especially when given through 
peripheral veins.  Many animals suffering from stressed starvation are insulin resistant 
and cannot completely utilize administered dextrose.  Additionally, malnourished patients 
commonly suffer from protein malnutrition which is not addressed by dextrose 
administration.   
• Lipids in parenteral nutrition 
Lipids are an efficient way to deliver energy and are often incorporated into PN 
solutions.  Lipid emulsions have several beneficial characteristics: they are isotonic, 
provide energy through gluconeogenesis, ketone body production, or fatty acid oxidation, 
and are the building blocks of cellular membranes.  The addition of lipid substrates to the 
PN admixture reduces the volume of dextrose required to meet an animal’s energy 
requirements and thus reduces the solution’s osmolarity.   
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However, controversy exists regarding the inclusion of lipids in PN, especially 
PN that is administered to critically ill animals.  Some current research suggests that lipid 
use and uptake (lipolysis) may be inhibited by the presence of insulin.43  Thus, concurrent 
administration of dextrose and lipids may result in inefficient lipid utilization when the 
dextrose stimulates insulin release.43 However, research in healthy dogs indicates that 
despite an increase in insulin concentrations, PN solutions with lipids as the main source 
of energy do provide adequate energy.44 It is unknown if these findings apply to patients 
with altered metabolism during illness.    
There is also a concern that in conditions of widespread inflammation (ie. sepsis),  
parenterally-administered lipids may amplify the inflammatory response.43 Most 
commercial lipid preparations have a predominance of n-6 fatty acids including linoleic 
acid.  Linoleic acid is a precursor for arachidonic acid which in turn is a precursor for 
many pro-inflammatory mediators such as thromboxanes, leukotrienes, and 
prostaglandins.45,46 Although these are essential fatty acids, recent studies suggest that 
exogenous lipid administration could lead to deleterious effects in patients with medical 
conditions perpetuated by inflammation, such as sepsis.43,45,46   
One study compared n-6 fatty acids with n-3 fatty acid preparations in human 
patients with sepsis.45 This study found that n-6 fatty acids (such as linoleic acid) 
upregulated endotoxin-induced monocyte cytokine production during sepsis, worsening 
inflammation.  Interestingly, those patients receiving n-3 fatty acids showed suppression 
of proinflammatory cytokine production by monocytes, suggesting the possible value of 
lipid substrates rich in n-3 fatty acids in the formulation of future parenteral nutritional 
solutions.45,46  
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Additionally, a retrospective study in humans showed that patients receiving 
parenteral lipids had decreased platelet activating factor acetylhydrolase (PAF-AH) 
versus patients who did not receive lipids parenterally.  PAF-AH inactivates platelet-
activating factor (PAF), a pro-inflammatory mediator that may be active in critically ill or 
stressed patients.47 Therefore, patients receiving parenteral lipid solutions may have an 
increased inflammatory response as a result of higher PAF activity.  Despite this, lipids 
are still considered a useful component of PN, as further studies are needed to determine 
the clinical significance of these findings.   
• Amino acids in parenteral nutrition 
 Amino acids are added to PN solutions to slow muscle breakdown and in theory 
to help maintain the integrity of the gastrointestinal tract and prevent atrophy.38 By 
sparing proteins in the muscles and other tissues, there are larger quantities of protein in 
the body to aid in the function of the immune system, play a role in wound healing, and 
improve the function of many organs.38,48  Simply providing non-protein energy in the 
form of glucose or lipids will spare protein catabolism to an extent, but some form of 
protein or amino acid supplementation is also required.48,49 A study comparing the 
nitrogen balance in healthy dogs administered electrolytes, dextrose-containing solutions, 
or amino acid-containing solutions demonstrated a negative nitrogen balance in all 
patients except those receiving amino acid supplementation.49  
• Other components in parenteral nutrition 
 Electrolytes, vitamins, and trace minerals are added to PN solutions to provide for 
non-energy daily nutritional requirements.  The Nutrition Advisory Group of the 
Department of Foods and Nutrition has published guidelines for parenteral vitamin, 
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electrolyte, and trace element supplementation in human patients receiving PN. 
Unfortunately, such guidelines are unavailable to direct veterinary PN composition, 
making vitamin and mineral supplementation of veterinary PN solutions variable.  
Components that are commonly added to veterinary PN solutions include B vitamins, 
vitamin D, and vitamin A; these are often found as multivitamin supplements.10,36,37  
Human formulations may also include iron, magnesium, or selenium35 while veterinary 
PN mineral supplementation is less standardized.   
Although long-term PN has been administered on an experimental basis to dogs, 
most clinical veterinary patients only receive PN for a short period of time in comparison 
to their human counterparts.  This minimizes the development of signs of mineral or 
vitamin deficiencies which humans on long term supplementation are more at risk of 
developing.35 Also, veterinary patients are typically placed on enteral nutrition as soon as 
possible (usually within seven days); enteral nutrition is adequately supplemented with 
vitamins and minerals.9,36  
 It is important that veterinary patients receive appropriate electrolyte 
supplementation while receiving PN.  In some cases, amino acid solutions contain 
electrolytes such as sodium, chloride, magnesium, and potassium which will typically 
supply the patient’s needs.  In other cases, the amino acid solutions are not combined 
with electrolytes.  In this situation, the patient should receive electrolyte-containing fluids 
through a separate intravenous catheter or a different port on the central line.37 As 
presented and discussed in chapter III, any patient receiving PN should have at least daily 
electrolyte panels performed in order to ensure that the patients’ electrolyte needs are 
appropriately supplemented.   
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Compounding PN solutions 
 Asepsis is extremely important in the formulation and administration of PN 
solutions.  Lipid-containing admixtures (dextrose, amino acids, and lipids) are 
significantly more supportive of bacterial and fungal growth compared to dextrose/amino 
acid solutions alone.50 However, with the advent of sterile formulations of lipids and 
sterile technique used by pharmacists when compounding PN solutions, contamination 
can be minimized in today’s formulations.34,51,52  To ensure the safety of PN 
formulations, human and veterinary pharmacies must adhere to comprehensive guidelines 
regarding PN compounding and formulation.11 
 Other concerns about the stability of PN formulations are minimized when PN is 
formulated by a pharmacist.  The stability of the PN formulation is dependent upon the 
techniques and order in which the components are added.  The Maillard reaction (aka. the 
browning reaction) refers to the negative interaction between amino acids (such as 
glycine) with carbohydrates.11,35 The brown color of the resulting solution is due to 
decomposition of carbohydrates.  The pharmacist must separately prepare and combine 
amino acids and carbohydrates to avoid this reaction.  Amino acid stability is also 
negatively affected by light; therefore, amino acid solutions must be carefully handled to 
avoid exposure to light during formulation of PN solutions.11,35  This includes keeping 
amino acid solutions covered both before and after they are added to the PN solution as 
well as while PN is administered to the patient.  However, if properly prepared and 
stored, dextrose and amino acid solutions are stable for several months.11,35   
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 Precipitation of PN components can occur.  The most commonly reported 
precipitation reaction is between calcium and phosphorus.11,35,53 To avoid this, calcium 
gluconate is used because it is the least reactive formulation of calcium available. Also, 
pharmacists add calcium and phosphorus separately in the compounding regimen to 
allow for maximal dilution of the two nutrients in the PN solution, minimizing the chance 
of precipitation reactions.11,35,53 In veterinary medicine, the composition of PN 
formulations vary widely and may or may not contain readily precipitant components 
such as calcium and phosphorus.   
 A third compatibility issue is the stability of lipid particles.11,35,53-55 Over time, 
lipid particles begin to associate together, forming a layer at the surface of the admixture.  
This phenomenon is known as creaming and can be reversed by agitation of the 
admixture.  Creaming occurs almost immediately after the lipid-containing admixture is 
compounded.  If particle association is unimpeded, lipid particles in the cream layer will 
then begin to associate together into aggregates (flocculation) which eventually leads to 
coalescence of lipid particles into larger particles.  
It is accepted in human medicine that when lipid particles greater than 5 µm in 
size make up more than 0.4% of a PN solution, embolization of pulmonary capillaries can 
occur.35,53,55 The exact time point of flocculation and coalescence varies depending on 
temperature of the solution, components of the solution, hang time of the bag of PN, and 
whether the bag has been agitated.  However, it is believed that unacceptable amounts of  
coalescence does not take place until the PN solution has been kept at room temperature 
for at least 24 hours.          
 Lipid particulate association is increased with decreasing pH and when 
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admixtures contain more cations than anions.11,14,35,53-56 Increased cation concentration 
neutralizes the negative charge on lipid particles, decreases electrostatic repulsion 
between lipids, and increases the likelihood of coalescence.  Appropriate formulation of 
PN solutions by a pharmacist is the best way to minimize the chance of these reactions.   
 Parenteral nutrition should only be compounded in specialized bags.  Parenteral 
nutrition bags are composed of several layers of ethylene vinyl acetate and other 
components to make them poorly permeable to air.  Air trapped in the bag during 
compounding or diffusion of air into the bag can result in air bubbles that oxidize PN 
components as well as trigger alarms in the intravenous pumps used to administer 
PN.14,53,57 Ethylene vinyl acetate is less likely to bind to components of PN (such as 
vitamins and lipids) which helps to protect the components of PN from oxidation 
reactions.14,53Additionally, bags not made of ethylene vinyl acetate have the potential of 
releasing carcinogens into the PN solution.53  
 
 
Obtaining and Administering PN 
Veterinary parenteral nutrition can be compounded at most pharmacies that 
prepare PN solutions for humans, since all components used are human products.  Some 
large veterinary referral institutions will formulate and ship PN to private practices as do 
commercial pharmacies.  Parenteral nutrition solutions can be formulated and stored for 
days or weeks at refrigerated temperatures (2-8ºC).14,25,29,35,52,53-55  However, once the PN 
formulation warms to room temperature, most institutions recommend changing PN bags 
daily as per FDA recommendations to avoid contamination and lipid particle 
destabilization.14  There is some debate regarding the longest amount of time that a PN 
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bag can be administered at room temperature with some institutions administering a 
single bag of PN for 48 hours or more.  However, there is little published data to support 
the safety of this deviation from FDA guidelines.58   
Traditionally, PN solutions in veterinary medicine have been administered 
continuously over 24 hours, largely due to their utilization at referral institutions where 
24 hour care is available.  However, the calculated daily energy requirements can safely 
be administered over shorter periods of time without adverse effects.50,59,60 One 
investigation demonstrated complete daily nutrient infusion over 10 hours in healthy 
dogs.59  The shorter administration time increases convenience of administration for 
situations when 24 hour monitoring is not readily available.  A case study describing the 
mistaken administration of 1800 mL of TPN solution in two hours to a German Shepherd 
dog (calculated hourly rate for this patient was 50 mL/hr) caused transient 
hyperglycemia, hyperlipidemia, and osmotic diuresis that was reversible by aggressive 
intravenous fluid therapy.61 Obviously, this infusion rate exceeds recommendations, but 
this case study demonstrates that TPN can be given without lasting negative effects at 
faster rates than those during a 24 hour continuous rate infusion.   
As mentioned above, veterinary TPN is administered through a central vein due to 
the high osmolarity of the solution.  Total parenteral nutritional solutions are always 
hyperosmolar compared to the plasma.  Normal plasma osmolarity is approximately 300 
mOsm/L, while TPN solutions are typically at least 850 mOsm/L, and commonly 1500-
2000 mOsm/L.  Hyperosmolar solutions can directly damage the tunica intima of blood 
vessels.  Also, red blood cells and other cells can lyse when they are exposed to a 
hyperosmolar environment in the bloodstream.  Therefore, TPN solutions must be 
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administered through a central venous catheter – typically one placed into or terminating 
in the jugular vein – to allow for dilution to an iso-osmolar solution; this occurs when 
TPN quickly mixes with a relatively large volume of blood in a central vein.  Early 
studies in Beagles proved the safety of administering hyperosmolar solutions through a 
central vein; hyperosmolar solutions up to 2400 mOsm/L were diluted by the 
bloodstream to isotonicity within 1.5 to 2.5 cm from the point of infusion into the central 
vein.1   
Another significant issue in the administration of PN is catheter-related infection 
introduced by catheter placement or improper handling of intravenous tubing or ports.  
Human medicine adheres to strict guidelines to prevent such complications and most of 
these guidelines have been adapted to veterinary medicine.62 (Table 5) 
Minimizing manipulation of and contact with the intravenous catheter, the 
administration set, and the PN bag itself – including routine line changes -- will lower the 
risk of catheter-related infections.  Human studies of 24 hour versus 72 hour PN line 
changes revealed a significant decrease in the incidence of nosocomial septicemia when 
changes were prolonged to 72 hours.63 The authors speculated that decreased septicemia 
was due to the fact that the majority of contamination was introduced through the open 
catheter hub during IV line changes.  In the case of patients receiving PN through a 
central catheter, multi-lumen central catheters do not have an increased risk of infection 
versus single lumen catheters as long as the lumen dedicated to PN is kept sterile as 
outlined in table 4 and is dedicated solely to PN.33,62,64   
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Summary 
Parenteral nutrition is a viable nutritional choice for small animal patients who 
cannot receive nutrition enterally.  It is possible to both obtain and administer PN in a 
private practice setting.  Parenteral nutrition formulations should be obtained from a 
pharmacy where appropriate protocols are followed to safely compound the solution.  
However, once the PN has been formulated, special equipment is not required for 
administration other than an aseptically placed and maintained catheter dedicated 
specifically to PN.   Chapter III details the formulation of a PN solution for patients as 
well as potential complications when administering PN.   
 
Key Facts 
1. Very few long-term studies investigating the clinical merits of parenteral 
nutrition administration exist in veterinary medicine; extrapolations from the 
human literature indicate that there is measurable improvement. 
2. Although most commonly used in the subset of patients unable to tolerate 
enteral nutrition, parenteral nutrition is a viable option for veterinary patients 
who cannot meet their caloric and energy requirements through enteral 
feeding alone.  A combination of PN and EN may be useful in this population 
of critical patients.   
3. Practitioners interested in parenteral nutrition need to utilize a pharmacy to 
compound their PN solutions.   
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Quiz (correct answer in boldfaced type) 
 
1. Which one of the statements below is most correct? 
a. Veterinary total parenteral nutrition (TPN) seeks to supply every nutrient 
need of the patient.    
b. Due to hyperosmolarity, veterinary PPN solutions are typically provided 
through a central vein. 
c. Veterinary PPN solutions are typically partial parenteral nutrition. 
d. a and b 
 
 
2. Veterinary total parenteral nutritional solutions are ___ to the plasma and ___ 
to partial parenteral solutions: 
a. Hyperosmolar; hyperosmolar 
b. Hyperosmolar; hypo-osmolar 
c. Hypo-osmolar; hyperosmolar 
d. Hypo-osmolar; hypo-osmolar 
 
3. Which statement is true about stressed starvation and uncomplicated 
starvation? 
a. Stressed starvation animals have insulin resistance whereas 
uncomplicated starvation animals have decreased insulin secretion. 
b. Stressed starvation animals have decreased insulin secretion whereas 
uncomplicated starvation animals have increased insulin resistance 
c. Simply feeding stressed starved animals will allow them to shift back to 
normal metabolism.  
d. None of the above 
 
4. Enteral nutrition is ____ compared to parenteral nutrition. 
a. Less physiologic 
b. More physiologic 
c. Equally physiologic  
d. None of the above 
 
5. Patients should begin receiving parenteral nutrition after __ days of decreased 
or absent nutritional intake? 
a. Immediately if the patient was undernourished prior to current sickness 
b. After 4-5 days of decreased or absent nutritional intake if patient 
appropriately nourished prior to current sickness 
c. After more than 7 days of decreased or absent nutritional intake 
d. Both a and b 
e. a, b, and c 
 
6. Which patient would be the best candidate for parenteral nutrition? 
a. Hepatic lipidosis cat that has not been vomiting 
b. Post-op gastrointestinal resection-anastomosis 
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c. Prolonged pancreatitis 
d. Anorexic patient that had received exploratory surgery for biopsies 
 
7. Which one of the following components of parenteral solutions contributes the 
most to the osmolarity of the solution? 
a. Dextrose 
b. Amino acids 
c. Lipids 
d. Vitamin additives 
 
8. Which of the statements is NOT a possible negative consequence of lipid 
administration? 
a. Inhibition of lipolysis in the presence of insulin 
b. Pro-inflammatory effects  
c. Provision of energy via gluconeogenesis 
d. There are no negative consequences of lipid administration 
 
9. Which of the following statements is NOT a possible sequela of the 
formulation of parenteral nutrition? 
a. Maillaird reaction 
b. Precipitation of calcium and phosphorus 
c. Lipid particle coalescence 
d. All of the above are possible sequelae 
 
10. Which of the below is an important procedure for parenteral nutrition 
administration? 
a. Clean and prep the skin aseptically 
b. Change the intravenous lines every 12 hours routinely 
c. Disconnect the intravenous lines when the patient is removed from the 
cage 
d. Mix all intravenous drugs in the parenteral nutrition solution prior to 
administration 
e. All of the above are important when administering PN 
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Chapter III.  A Primer on Parenteral Nutrition Part 2: Formulation, 
Monitoring, and Complications  
            
     
As decreased caloric and nutrient intake can complicate the course of both mild and 
serious illness, parenteral nutrition (PN) is an important feeding modality for patients 
unable to receive adequate enteral nutrition.  Many pharmacy facilities are capable of 
compounding PN formulations; with proper staff training and patient monitoring, PN can 
potentially be performed in many veterinary practices.  This chapter provides 
practitioners with basic information on the formulation and use of PN in their patients.  
Information is also provided on the monitoring of patients receiving PN as well as ways 
to overcome and identify the common complications of animals receiving PN.  
 Parenteral nutrition (PN) involves the intravenous administration of nutrients. 
Parenteral nutrition solutions are commonly mixtures of dextrose solutions, lipid 
emulsions, and amino acid solutions that variably contain electrolytes, vitamins, and 
mineral supplements (chapter II).  When dextrose, lipids, and amino acids are used 
together in a PN formulation, the resulting mixture is termed a “3-in-1 solution” or “total 
nutrient admixture.”   Three-in-one admixtures are easy to administer, provide for a 
patient’s short term energy needs in one solution, and are well tolerated by patients.35 
Dextrose and amino acid solutions, without lipids, are given to patients as well.  These 
solutions avoid any potentially negative side-effects of lipid administration, but because 
of their high osmolarity require substantially greater volumes of delivery to meet caloric 
needs (see chapter II for a full discussion of the possible drawbacks of lipid 
supplementation).  
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 Published opinions differ on the appropriate estimation of nutrient requirements 
for a patient.  For the purposes of the following discussion, we will describe the 
formulation method used by the University of Missouri-Columbia Veterinary Teaching 
Hospital and several other veterinary colleges.  The formulation is based on descriptions 
of Remillard and Thatcher37 and Lippert and Armstrong66 and is similar to other methods 
described in the veterinary literature.36,42,67 However, research is ongoing in the field of 
veterinary nutrition, and the future may hold alterations to this formulation.   
 
Total Parenteral Nutrition Formulation 
For a complete case example of formulating TPN, see tables 6 and 10.   
 
 The BER or basal energy requirement is a measured approximation of the energy 
expenditures for an animal under a set of restricted conditions including environmental  
temperature and animal activity level.  It is typically used as an approximation for a 
patient’s resting energy requirement (RER) which describes an animal with a minimal 
activity level in unrestricted conditions.37 Often the BER and RER are used 
interchangeably in the literature.  For the body weight range indicated, the first BER 
equation is a useful linear interpolation of the second equation, which is commonly 
known as the Kleiber-Brody equation.   
Step I: Calculate the basal energy requirements (BER) 
 BER (kcal/day) = (30 × BWkg) + 70   for patients ≥2 kg and ≤45kg 
 BER (kcal/day) = 70(BWkg) 0.75                for patients <2 kg and >45kg 
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 A recent publication indicates that neither equation is a perfect estimation of BER 
for individual animals – the equations better represent the energy needs of populations of 
animals.68 Nonetheless, the equations are commonly used as a starting point for BER 
estimation.  Some sources propose using the following equation for feline energy 
requirements: BER = 40 × BW(kg).58  Proponents of this equation argue that for “typical” 
adult cats ranging between 2 and 6 kg, the total calculated caloric intake is too great when 
(30 × BWkg) + 70 is used to estimate BER and, by extension, patients are being 
oversupplemented.   
 
 
 
 
 
Traditionally, illness factors range from 1.0 to 2.0.  Under the current system at 
the University of Missouri-Columbia, a burn patient would be assigned an illness factor 
of 2.0 to provide for increased losses of protein and fluid through cutaneous wounds.  A 
patient in a hypermetabolic condition such as sepsis would have an illness factor of 1.7, 
whereas a patient without severe trauma or body protein losses would require only BER 
and thus an illness factor of 1.0.  These factors were initially derived from research in 
humans during the late 1970s and 1980s.  The factors have been reported and repeated in 
the veterinary literature without direct verification of their use in animals, and therefore 
may not be valid in animals.37 
Step II: Determine TER (total energy requirement) 
TER = BER multiplied by an illness factor37  
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The validity of multiplying the BER by an illness factor has recently been 
questioned.58,69 It has been shown in recent human studies that during periods of illness or 
post-trauma, the body naturally transitions to a catabolic state.  Insulin resistance occurs 
and transient hyperglycemia may result.  In this state, regardless of the amount of 
dextrose infused, the body is unable to make full use of it; this contradicts a traditional 
mind-set of supplying large amounts of dextrose to stressed patients to meet their energy 
needs.  More recent studies in humans have also shown that increasing protein (as amino 
acids in PN) above the patient’s basal metabolic needs does not effectively counter 
protein catabolism during periods of stress or illness.69,70 Amino acids not utilized for 
body protein needs will result in use of the amino acids for generation of energy and 
result in proportionally increased metabolic urea and ammonia production. 
Therefore, the practice of multiplying the BER by a factor to supply greater 
amounts of energy as protein (in the form of amino acids), dextrose, and lipids may not 
benefit a patient and may actually be detrimental.  There is agreement within the human 
literature that during stress and illness, a human patient’s energy requirements do not 
increase more than 1.2 × BER.69 Thus, the current movement in veterinary medicine is 
away from utilizing illness factors for all patients in energy requirement calculations.  
Instead, illness factors are reserved for use on a case by case to avoid 
oversupplementation of patients, leading to hyperglycemia, liver dysfunction, or 
unwanted metabolic acid and ammonia production.58   
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As discussed above and in chapter II, parenterally administered amino acids are 
used to replace amino acids lost in protein turnover and other biochemical pathways.  It 
should be appreciated that during both the fed and food deprived state, amino acid 
catabolism is always occurring, albeit at different rates. Hence, irrespective of whether 
protein requirements are met by amino acids given in PN admixtures, catabolism of 
amino acids always makes some contribution to body energy needs.    
Although energy production from amino acid catabolism is well recognized, 
many parenteral formulations currently utilized in veterinary medicine (including the 
present formulation) do not account for energy derived from admixture amino acids.  
Such formulations are prepared so that the animal’s energy requirement is completely 
supplied as dextrose and lipids.  The is concern that the majority of supplemented amino 
acids will be converted into energy, rather than be used for protein synthesis and other 
anabolic processes, if insufficient energy is supplied to the patient from other sources.37 
Also, excessive amino acid supplementation may lead to the excretion of nitrogenous 
wastes, such as urea, using the very energy derived from the supplemented dextrose and 
lipids.37   
Step III: Determine the protein requirement37,66
Typically:  Adult cats    6g/kg/day 
Renal/hepatic disease cats  3 g/kg/day 
Adult dogs                4 g/100 TER kcal/day 
Renal disease dogs    1.5 g/kg/day  
Extraordinary protein loss dogs           6 g/100 TER kcal/day 
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For optimal utilization of parenteral amino acids in anabolic processes, it is 
believed that amino acids should be given in a certain proportion with energy. For this 
reason, protein requirement (in amino acids) is determined per 100 kcal of TER in dogs.37  
Because variation in body weight among adult cats is considerably less than among adult 
dogs, the optimal protein to energy ratio in cats is suitably expressed as a ratio of grams 
of protein per kilogram of body weight. 
A 2001 study was conducted to determine the protein requirements of 
parenterally-fed normal dogs using nitrogen balance methodology.48 It examined the 
presently used 4 g/kg/day estimation of canine protein requirements which originated 
from a 1968 publication reporting research on PN in adult beagles.6 The recent work 
indicates that 2.3 g/kg/day is the intravenous amino acid requirement for clinically 
normal dogs fed their maintenance energy requirements (roughly equivalent to 2 × 
BER).48  At this time, it is unclear whether this amount of protein can be used in diseased 
dogs when supplying only BER, but it is possible that the protein requirement for dogs 
may be significantly less than the 4 to 6 g/kg/day traditionally utilized as the daily protein 
requirement.   
A study evaluating the effects of dietary protein restriction and amino acid 
deficiency on canine protein metabolism in dogs fed enterally concluded that a healthy 
dog’s typical daily nitrogen requirement is 0.41-0.55 g /(kg0.75).71  A recent study 
performed on healthy adult cats fed enterally concluded that cats require 2.7 g/kg/day of 
crude protein to meet their needs.72 Both studies suggest that actual protein and amino 
acid requirements may be lower than current recommendations in cats and dogs.  
However, because both of these studies involved enteral provision of nutrients, it is 
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difficult to know the relevance of these findings to parenteral nutrition formulation.  In 
addition, these were healthy animals, and a direct correlation to systemically ill pets 
cannot be inferred.  
  
 
 
1. Dextrose solution                             
The dextrose solution most often used in TPN admixtures is 50 % (500 mg/mL) dextrose 
and contains 1.7 kcal/mL. Patients typically receive 40 to 60% of their energy 
requirements from dextrose.  As hyperglycemia is a complication of PN, it may be better 
to provide closer to 40% of the energy requirements as dextrose to patients at risk of 
insulin resistance.   If such an alternative formulation is used, additional energy 
requirements must be supplied through increasing the lipid portion of the PN solution.  In 
order to deliver 60% of a patient’s energy (TER) from dextrose, calculate the volume of 
solution using the following equation: 
 
 
 
 
2. Lipid emulsion 
The lipid emulsion most often used in TPN admixtures is 20% (200 mg/mL) vegetable oil 
lipid and contains 2.0 kcal/mL.  Ten and 30% lipid emulsions are used in special cases.  
Step IV: Determine the volume of nutrient solutions required 
TER × 0.60  = ___kcal/day of dextrose ÷ 1.7 kcal/mL 
 = ___ mL of 50% dextrose per day 
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Patients typically receive 40-60% of their energy requirement as lipid.  For 40% of 
energy (TER), calculate the volume of 20% lipid emulsion using the following equation: 
 
 
  
 
3.  Amino acid solution  
As with dextrose solutions and lipid emulsions, amino acid solutions are available in a 
variety of concentrations. The most commonly used solution is 8.5% (85 mg/mL) amino 
acids available with and without electrolytes. The following equation is used to calculate 
the volume of this solution: 
 
  
 
 
 
Step V: Determine the total volume of TPN solution   
 
___ mL total of dextrose + ____mL total of lipids + ____mL total of  amino acids 
Divide by 24 hours to determine the mL/hr 
1st day typically administer 1/3 of this rate. 
2nd day typically administer 2/3 of this rate. 
3rd day typically administer at the full calculated daily rate. 
RER × 0.40  = ___ kcal/day of lipids ÷ 2 kcal/mL 
 = ____ mL of 20% lipid solution per day 
_____ g protein/day ÷ 85 mg/mL × 1000mg/g 
  = ______ mL per day 
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Most patients are gradually introduced to TPN to avoid rebound hyperglycemia 
and other electrolyte abnormalities from the sudden infusion of large concentrations of 
dextrose (see chart 1 and the discussion under Patient Monitoring).  The patient may 
require additional intravenous crystalloid (IV) fluids through another IV port to meet 
daily maintenance fluid and electrolyte requirements.  In patients with severe electrolyte 
disturbances -- such as diabetic ketoacidotic patients – the use of amino acid formulations 
without electrolytes may simplify case management.  In such cases, electrolyte-
containing solutions can be administered through a separate IV catheter to allow more 
controlled titration and provision for electrolyte deficits.  
 
 
                                     
 If the patient will not be receiving enteral nutrition for more than 5 to 7 days, the 
clinician may want to also supplement with 0.5 mg/kg vitamin K1 subcutaneously once 
weekly.   
Virtually all sources indicate that B vitamins should be supplemented in patients 
receiving TPN.36-38,42  B vitamins are essential for utilization of the dextrose, lipid, and 
amino acids delivered in the PN solution, and most patients ill enough to receive PN have 
B vitamin deficiencies.  However, the actual amount of B vitamins required by critically 
ill animals and the amount added to PN solutions varies widely in the veterinary 
literature.   
The exact formulation and dose of B vitamins supplemented is also rarely 
mentioned.  Original sources recommend that the B vitamin preparations include at least 
Step VI: Determine the daily vitamin requirements 
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5-7 of the “important” B vitamin types (i.e., folic acid, thiamin, riboflavin, niacin, 
pantothenic acid, pyridoxine, B12)  but do not specify a particular preparation nor a 
dosage.2 An oft-published B vitamin supplementation recommendation is to add 1 mL of 
B complex vitamins per 100 kcal of energy supplied in the PN admixture36; this amount 
will supply more than the minimum nutritional requirements of B vitamins for adult dogs 
and cats as determined by the National Research Council on the Nutritional Requirements 
of Dogs and Cats.15 Bear in mind however that those requirements reflect enteral nutrition 
and may not be correct when nutrition is supplied parenterally.   
At our institution, a vitamin B complex solution is used that contains (per mL) 
12.5 mg of thiamine HCl, 12.5 mg of Niacinamide, 2 mg of riboflavin, 5 mg of d-
Panthenol, and 0.2 ppm Cobalt as vitamin B12. One mL of the solution per 100 kcal of 
TER is estimated to well exceed the dietary requirement of dogs and cats. 
 
Partial Parenteral Nutrition Formulation74 
 
If one is administering 3-in-1 admixtures of PPN containing lipids, dextrose and amino 
acids, the following guidelines apply.  For a complete case example, see tables 7 and 11.  
 
 
 
 
1. Step I:   Calculate TER as detailed in steps 1 and 2 above 
2. Step II:  Partial daily energy requirement (PER) = 50% × TER 
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This variation in PPN solution composition is an attempt to keep the total volume 
consistent across patients of varying weights.  However, patients less than 3 kg will still 
receive a volume of fluid greater than their daily maintenance fluid requirements in order 
to fulfill their daily energy requirements.  Additionally, it is interesting to note that this 
formulation of PPN treats the amino acids purely as energy sources which contribute to 
the overall PER rather than purely to support muscle anabolism as with TPN.  Since 
patients receiving PPN are not receiving all their nutritional requirements, they should 
ideally simultaneously receive enteral nutrition.   
 
 
 
 
3. Step III:  Determine the calorie sources for the patient.  
• It is recommended that a dog or cat under 10 kg receive 25% of PER as 
dextrose, 25% as amino acids, and 50% as lipid. 
• A dog between 10 and 25 kg can receive its energy requirements equally from
 dextrose, amino acids, and lipids (ie. 33% of its energy requirements from
 dextrose, 33% from amino acid sources, and 33% from lipid sources).  
• A dog over 25 kg should receive 50% of its energy requirements from  
dextrose, 25% from amino acid sources, and 25% from lipid sources.   
4. Step IV: Determine the volume of nutrient solutions required 
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1. Dextrose  
  
 By using 5% dextrose rather than 50% dextrose, the resulting osmolarity of the 
PN solution will be much less than that of TPN and therefore make the solution safe to 
administer through a peripheral vein.  (See chapter II for a more complete discussion of 
osmolarity).   
 
2. Lipids 
 
3. Amino Acids 
  
 An alternative method used by some practitioners to reduce PPN osmolarity is to 
use 3.5% amino acid solutions instead of 8.5% solutions.  These 3.5% solutions contain 
3.5 g of protein/L and have a reduced osmolarity versus 8.5% amino acid solutions.  It is 
recommended that other sources be consulted for exact PPN formulations using 3.5% 
amino acid solutions prior to their use.   
5% (50 g/dL) dextrose solution = 0.17 kcal/mL 
PER × % calories as dextrose = ___ kcal/day dextrose ÷ 0.17 kcal/mL = ___ mL/day 
20% (200 g/L) lipid emulsion = 2 kcal/mL 
PER × % calories as lipid = ___ kcal/day lipids ÷ 2.0 kcal/mL = ___ mL/day 
8.5% (8.5 g/L) amino acid solution = 0.34 kcal/mL 
PER × % calories as amino acids = ___ kcal/day ÷ 0.34 kcal/mL = ___ mL/day 
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 PPN is typically started at the maintenance rate immediately although it can 
initially be given at half of the calculated rate for the first 6-12 hours and then increased 
to the full calculated rate.58 PPN solutions are much less likely to induce hyperglycemia 
and refeeding syndrome than TPN, and thus less importance is placed on gradually 
introducing the PPN solution to the patient.   
 
 
  
 
If the patient will not be receiving enteral nutrition for more than 5-7 days, the 
clinician may want to supplement with 0.5 mg/kg vitamin K subcutaneously once 
weekly.             
 Most sources indicate that B vitamins should be supplemented in patients 
receiving PPN.  However, this recommendation varies widely with each publication and, 
as discussed above with TPN formulations, the exact components of the B vitamin 
complex are not directly defined in any source.  Just as with TPN, a commonly stated B 
vitamin supplementation is to add 1 mL of B complex vitamins per 1000 kcal of energy 
supplied in the PN admixture.73 Also, as with TPN, the assumption is made that 
5.  Step V:   Determine the total volume of PPN solution per day 
____ mL total of dextrose + ____mL total of lipids + ____mL total of  amino acids 
Divide by 24 hours to determine the mL/hr 
6.  Step VI:   Add in vitamin supplements 
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nutritional requirements for parenteral nutrition are the same as those for enteral 
nutrition.    
________________________________________________________________________ 
Alternative PPN sources 
 An alternative to the 3-in-1 admixtures with lipids, dextrose, and amino acids is 
the use of PPN solutions with only amino acids and/or dextrose.  There are several 
solutions available commercially.  One such formulation is a mixture of 3% amino acids, 
glycerol, and electrolytes (available commercially or created by mixing 300mL of 8.5% 
amino acid solution with 700 mL of LRS plus 5% dextrose).  Such a solution can be 
administered continuously for longer than 24 hours because it does not contain lipids 
which deteriorate over time.  The published rate for this solution is 40-45 mL/kg/day.75 A 
downside to this preparation is that it does not attempt to meet vitamin requirements in 
the patient and its osmolarity is higher than a 3-in-1 PPN admixture because it does not 
contain iso-osmolar lipids to dilute the hyperosmolar dextrose and amino acids.  
However, these PPN sources are advantageous in that the practitioner can either purchase 
the pre-mixed solutions or easily prepare them from readily available supplies using 
appropriate aseptic technique. 
Be aware that when PPN and TPN solutions are metabolized, the solution is 
broken down to release a volume of free water equivalent to the volume of solution.  PPN 
calculations (especially for the 3-in-1 admixtures) may require the use of a larger volume 
of solution than is practical or safe to administer to a given patient.  It is also possible that 
larger patients will require additional electrolyte fluid solutions to completely meet their 
daily requirements, especially if the patient is in need of a high rate or volume of fluids.  
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Also, if electrolytes are not added to PPN solutions or if the patient has many electrolyte 
abnormalities, the patient will require concurrent administration of electrolyte-containing 
fluids intravenously through another IV catheter.   
 
Patient Monitoring 
Careful monitoring of patients receiving parenteral nutrition is important to 
identify and rectify any metabolic abnormalities that develop during the period of 
feeding.37,42,58,67  Recommendations vary, but all sources agree that vital signs (ie. 
temperature, pulse, respiratory rates, patient attitude) should be serially monitored every 
4 to 6 hours for the first 2 to 3 days and at decreasing frequency after that time.  Body 
weight should be measured every 12 to 24 hours.  
Blood and urine glucose should be evaluated at least every 12 hours for the first 2 
to 3 days for evidence of hyperglycemic complications.  All sources agree that if the 
patient’s blood glucose is elevated persistently over 200 mg/dL in a patient, steps should 
be taken to combat hyperglycemia.37,58,67  Some clinicians would be more aggressive and 
begin to address hyperglycemia at much lower blood glucose concentrations.  Steps to 
address hyperglycemia include initially decreasing the PN fluid administration rate and 
potentially administering regular insulin to bring the blood glucose back into the normal 
range.37,58  Insulin can be administered by intermittent intramuscular or subcutaneous 
injection or given as a constant rate intravenous infusion of 1 to 2 U/kg/24 hours for dogs 
or at a starting dose of 1 U/cat.58 Regular insulin is the insulin of choice to use in these 
situations because of its short duration of action and the ease with which the dosage can 
be altered.  A third option to combat persistent hyperglycemia would be to reformulate 
the PN solution with a smaller percentage of dextrose and a greater percentage of amino 
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acids and/or lipids to provide for energy requirements.  Retrospective studies in 
veterinary medicine reveal that while common and usually transient in the majority of 
cases, many animals suffering from hyperglycemia will require at least temporary insulin 
therapy.10,41,76,77   
Some authors feel that the blood glucose monitoring regimen should be more 
strict in order to avoid any chance of PN-induced hyperglycemia, especially for the first 
days of PN supplementation.58 (see Figure 1) Following Figure 1, if the blood glucose 
concentration at subsequent rechecks remains between 250 to 300 mg/dL, the PN 
infusion rate should be decreased to the highest rate of infusion that maintains the blood 
glucose concentration below 250 mg/dL.  If the blood glucose concentration rises above 
300 mg/dL, the PN infusion rate should be decreased and the patient may need insulin 
therapy.   
Serum electrolytes and renal parameters are also important to monitor at least 
every 24 hours for the first two to three days of parenteral nutrition administration and, if 
no complications are seen, less regularly thereafter.  Evidence of hypokalemia, 
hypophosphatemia or other changes consistent with the refeeding syndrome can be 
handled as described below (see Refeeding Syndrome section).  Azotemia – especially 
increases in blood urea nitrogen (BUN) – may be due to excessive protein 
supplementation and can be addressed by decreasing the amino acid content of the PN 
admixture.   
Some authors feel that packed cell volume (PCV) and total protein (TP) 
parameters should be serially monitored in patients on PN.67 Others feel that a patient’s 
blood should be checked at least every 12 to 24 hours for evidence of lipemia via visual 
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inspection of the serum and/or through examination of serial triglyceride measurements 
for the first 2 to 3 days and then with decreasing frequency thereafter.37 Lipemia might 
indicate excessive administration of lipid sources and can be addressed by decreasing the 
lipid proportion of the feeding admixture.   
It is clear from all sources that animals receiving PN should be closely and 
serially monitored to identify and allow for correction of metabolic abnormalities.  
Similarly, as dictated by common sense, a patient should slowly be weaned off PN 
sources over the course of at least 12 to 24 hours to decrease rebound hypoglycemia or 
other electrolyte changes that could be induced by abrupt cessation of nutritional 
support.58 
Other parameters typically monitored in patients receiving PN at the University of 
Missouri include central venous pressure measurements (CVP) -- especially in animals 
receiving additional isotonic crystalloids or electrolyte solutions with their PN.  This is 
accomplished by utilizing a multi-lumen central venous catheter in the patient – one 
lumen is dedicated to PN administration and the other lumen can be used for CVP 
monitoring.  Serial CVP measurements are used to prevent volume overload while 
patients are receiving nutrition.  Checking the patient’s serum osmolarity every 24 hours 
will ensure that the PN solution is not causing the patient’s serum to become 
hyperosmolar.  Both increases in CVP or serum osmolarity can be addressed by 
decreasing the rate of PN administration or decreasing the amount of dextrose 
administered in the solutions.  Finally, visual inspection of the catheter site should be 
carried out at least every 12 hours.  Extravasation of PN solutions leading to local tissue 
inflammation and necrosis is a potential complication of PN.  If extravasation is detected, 
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the PN catheter must be removed and replaced in another location.  Ice packs and 
hydrotherapy can be administered to the affected region.   
 
 
Disadvantages of Parenteral Nutrition 
 
The drawbacks of parenteral nutrition can be divided into four main categories: 
infection, mechanical complications, cost, and metabolic complications.   
Infection occurs secondary to contamination and growth of bacteria and fungi in a 
PN bag, nosocomial bacterial or fungal contamination during the administration of PN, or 
infection introduced by bacterial translocation from the patient’s own body -- specifically 
the gastrointestinal tract or skin at the catheter site.  Contamination of the PN bag during 
compounding and nosocomial infection introduced during administration of PN can be 
controlled by careful preparation of PN and aseptic handling of the IV tubing as 
discussed in chapter II and reviewed in Table 8.  Mechanical complications include IV 
line breakage or kinking, patient destruction of IV lines or catheters, clogging of the IV 
lines, and thrombophlebitis.  Careful monitoring of patients can help to minimize these 
occurrences and use of polypropylene catheters have been shown to decrease the 
incidence of thrombophlebitis.78-80 Metabolic complications such as biochemical or 
electrolyte abnormalities, may be induced by the administration of PN to a patient and 
can include hyperglycemia, hypophosphatemia, and hypokalemia.   
In a retrospective study of PPN administration in small animals, metabolic, 
mechanical and septic complications were reported.41 In this study, hyperglycemia (blood 
or serum glucose>120 mg/dL) was the single most frequently encountered metabolic 
complication.  Other noted complications included hyperbilirubinemia, lipemia, and 
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azotemia.  No patients required insulin therapy, and the hyperglycemia improved within 
one to three days.  The likelihood of metabolic complications was not found to be 
significantly different between cats and dogs.  Mechanical complications were more 
common in dogs (26% of dogs vs. 9% of cats) and included occlusion of catheters, line 
breakage, disconnections, and thrombophlebitis.  There was only a 3% reported rate of 
septic complications.   
In two retrospective studies of TPN usage in both dogs and cats, mechanical 
complications were frequent.76,77 Forty-six percent of the mixed canine and feline 
population described by Lippert et al76 had mechanical complications as compared to 
21% of the feline only population described by Pyle et al.77   Hyperglycemia (>140 
mg/dL18 and >134 mg/dL77 respectively) was another common complication experienced 
by 75% of all cats76 and 47% of non-diabetic cats77 experiencing hyperglycemia.  
Similarly, 46% of all dogs76 had high blood glucose values (>140 mg/dL) while receiving 
TPN.  Other metabolic derangements detected in animals receiving TPN were hypo- and 
hypernatremia, hyper- and hypokalemia, hypo- and hypercalcemia, and hypo- and 
hyperphosphatemia.  However, the occurrence of these abnormalities was much less 
common than hyperglycemia – at the most 10% of Lippert et al’s canine and feline 
populations and at the most 34% of Pyle et al’s feline only population.   Lipemia was 
noted in 46% of cats and dogs76 and 24% of cats.77 
Clinical signs attributable to metabolic complications were rare in both studies, 
although some patients did require insulin administration for persistent hyperglycemia 
(greater than three days duration).76,77 Lippert et al76 reported that 36% of hyperglycemic 
dogs and 67% of hyperglycemic cats required insulin therapy.  Although Pyle et al77 did 
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not report a percentage of cats requiring insulin, the majority of hyperglycemic cats did 
require insulin therapy.  There was an overall low rate of septic complications with 
Lippert et al showing no septic complications in either cats or dogs and Pyle et al finding 
TPN-associated sepsis in only 5 of 84 cats.   
Parenteral nutrition is not an inexpensive feeding modality.  PN components are 
fairly inexpensive individually, but when combined into admixtures, the cost of each 
component is additive.  Also, when formulated by a pharmacy, there is a dispensing and 
formulation charge to provide for costs associated with use of the laminar flow hood, the 
physical materials needed to compound the solution (syringes, needles, tubing, etc), and 
cost for the expertise and time of the pharmacist.  The specialized ethylene vinyl acetate 
PN bag also carries a substantial cost.  At the University of Missouri-Columbia 
Veterinary Medical Teaching Hospital, the bag itself represents 33% of the daily cost of 
PN.  When all this is taken into account, the cost per day of PN will be upwards of 
$100/day for the client and, as such, may be cost prohibitive or limit the duration that PN 
can be provided for a patient.   
 
 
The Refeeding Syndrome 
 
The refeeding syndrome is a complication of nutritional supplementation that, 
although possible in our veterinary patients, is more commonly reported in humans.  It is 
a syndrome of severe hypophosphatemia, hypokalemia, hypomagnesemia, and other 
electrolyte derangements that can be induced in an anorectic, malnourished patient by 
providing nutrient supplementation (oral, enteric, or parenteral).81,82 Patients typically 
suffer from hyperglycemia as well.  Hyperglycemia and concurrent glucosuria can lead to 
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osmotic diuresis -- resulting in sodium and water loss.  However, in other cases, 
especially in patients fed mainly with carbohydrate sources, feeding leads to reduced 
sodium and water excretion and, in some cases, can lead to increases in extracellular fluid 
volume and eventually peripheral edema.82   
Hypophosphatemia is the most significant feature of the refeeding syndrome in 
humans.81-83 It occurs when there has been starvation-induced loss of lean muscle mass, 
minerals, and water.  The patient’s whole body phosphorus is depleted in this stage, 
although bloodwork typically does not reflect this.  When nutrition is provided to such a 
patient, the presence of carbohydrates causes the release of insulin.  Insulin induces an 
intracellular shift of phosphorus, causing clinically measurable serum hypophosphatemia.  
As the patient is fed, there is a conversion from catabolism to anabolism and the body 
begins to create cell membranes, nucleic acids, adenosine triphosphate (ATP), and 2,3-
diphosphoglycerate (2,3 DPG) – all of which require phosphorus.  This demand for 
phosphorus in turn magnifies the pre-existing hypophosphatemia.   
The refeeding syndrome is a clinically recognized syndrome that typically occurs 
about three days after initiation of nutritional intervention.81,82 Hypophosphatemia leads 
to decreased cardiac contractility through an undefined mechanism and decreased white 
blood cell function.  A wide spectrum of neuromuscular dysfunction can occur ranging 
from muscular paralysis, to cranial nerve deficits and ventilatory dysfunction.  These 
neuromuscular changes may be due to hypoxic cellular injury resulting from decreased 
oxygen delivery to tissues due to decreased 2,3-DPG in red blood cells.  Hypoxia may 
also result from decreased red blood cell delivery to tissues through capillary beds as red 
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blood cell membranes lose their pliability when the patient is hypophosphatemic.  Severe 
hypophosphatemia may also lead to hemolytic anemia.  
Hypomagnesemia and hypokalemia can cause similar clinical signs to 
hypophosphatemia, including cardiac arrhythmias, weakness, seizures, and ataxia.82,83 
The functions of magnesium are not completely characterized, but seem to parallel 
phosphorus and potassium in cellular actions.  Both hypokalemia and hypomagnesemia 
occur in the refeeding syndrome mainly from the increase in insulin and accompanying 
shifting of potassium, magnesium, and phosphorus into the cells, leading to decreased 
concentrations of serum potassium and magnesium.81-83 
Patients suffering from prolonged anorexia or starvation should be gradually 
introduced to parenteral and enteral feeding over the course of two to three days to 
acclimate the body to the infusion of calories when it has been in a starvation state, in 
turn minimizing the chances of inducing the refeeding syndrome.  The patient should be 
carefully monitored, including serial electrolyte and blood glucose monitoring during the 
first days of patient supplementation.  Not every patient will undergo this syndrome, but 
potentially every patient is at risk.   
Although recognized and reported in humans, there are few veterinary 
publications that explicitly address the refeeding syndrome in animals.  As noted 
previously, both hypo- and hyperphosphatemia were reported in animals placed on TPN 
and PPN.76,77 These studies had a slightly greater prevalence of hyperphosphatemic 
complications than hypophosphatemic, although the numbers were very small in both 
studies.  These studies were both retrospective and did not directly address reasons for 
these electrolyte abnormalities.  A single veterinary case study describing the refeeding 
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syndrome in a chronically anorexic cat was characterized by severe hypokalemia and 
normal phosphorus concentrations.84  
If persistent hypophosphatemia results from the administration of PN, the patient 
can receive intravenous phosphorus supplementation. The recommended phosphorus 
dosage is 0.003 mmol/kg/hr intravenously for the first 24 hours or 0.03 mmol/kg/hr for a 
total of six hours.83 Although typically not possible in animals receiving PN, hypokalemia 
is best treated by oral supplementation.  However, it can also be addressed through the 
addition of potassium to the intravenous fluids that the patient is receiving (see Table 
9).85  
Magnesium is administered in patients with serum total magnesium 
concentrations below 1.2 mg/dL (normal range 1.7 to 2.4 mg/dL).86 Magnesium 
supplementation should be administered as a 20% dilution by combining MgSO4 or MgCl 
with 50% dextrose.  This solution can be given as a constant rate infusion of 0.75-1.0 
mEq/kg/day for the first day, followed with 0.3 to 0.5 mEq/kg/day of the diluted 
magnesium solution for an additional three to five days.  As an alternative in certain 
patients, oral supplementation of magnesium (magnesium oxide or magnesium hydroxide 
supplements) may be given at a dosage of 1 to 2 mEq/kg/day.   
 
Summary 
Parenteral feeding through TPN and PPN administration provides nutrition to 
improve clinical outcome, but also comes with substantive cost and inherent 
complications.     Careful monitoring of patients while they are receiving PN can help to 
identify and allow for correction of these complications.  It is important to have a 
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dedicated nursing staff that will closely monitor the patient receiving PN to avoid 
mechanical complications.  Frequent blood draws and biochemical analyses over the first 
2 to 3 days of PN administration can help to identify any metabolic complications.  
Careful compounding and sterility when handling PN can reduce infectious 
complications.  Overall, parenteral nutrition is a viable option for those patients who 
cannot receive food enterally.   
 
Key Points 
1. Patients benefit from parenteral nutrition, but they frequently suffer from at least 
transient hyperglycemia and may require insulin supplementation. 
2. Future refinements in parenteral formulations for dogs and cats are expected. 
These refinements will probably come with evidence of improved clinical 
outcomes in dogs and cats.    
3. The refeeding syndrome can be induced in a patient fed enterally or parenterally; 
all patients need to be monitored for this potentially (albeit rare) side effect.   
 
 
Quiz (correct answer in boldface type) 
1. What is the most important role of protein as amino acids in parenteral 
nutrition? 
a. Providing another energy form to the body. 
b. Providing a substrate for glucose metabolism. 
c. Providing a substrate for muscle anabolism.  
d. Reducing the osmolarity of the PN solution. 
 
2. Which one of the following statements is true? 
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a. In a total parenteral nutritional solution, typically patients receive 40% 
of their energy requirements from amino acids. 
b. All patients routinely receive vitamin C supplemention in parenteral 
nutritional solutions. 
c. The parenteral nutritional line and tubing should be changed every 12 
hours to preserve asepsis. 
d. Begin total parenteral nutritional solution delivery at a reduced 
rate and adjust upwards to the full calculated administration rate 
over the course of 1-2 days if the patient is tolerating the solution.   
 
3. Which one of the following sets of parameters is important to routinely 
monitor in all patients when administering parenteral nutrition? 
a. Glucose, BUN, repeat patient TPR 
b. Glucose, phosphorus, amylase 
c. Glucose, urine specific gravity, creatinine 
d. Glucose, sodium, chloride 
 
4. What are three reported metabolic complications of parenteral nutritional 
administration? 
a. Hyperglycemia, hyperphosphatemia, lipemia 
b. Hyperglycemia, hypophosphatemia, lipemia 
c. Hypoglycemia, hyperphosphatemia, hypoalbuminemia 
d. Hypoglycemia, hyperphosphatemia, hyperalbuminemia 
 
5. What are important categories of disadvantages to parenteral nutrition 
described in the veterinary literature? 
a. Infection 
b. Cost 
c. Metabolic 
d. All of the above 
 
6. Which one of the following is the most commonly reported complication of 
parenteral nutrition in the literature? 
a. Hyperglycemia 
b. Mechanical complications 
c. Infection introduced into the parenteral nutrition bag during 
compounding 
d. Sepsis 
 
7. What steps should be taken when there is extravasation of parenteral nutrition 
solution at the catheter site? 
a. Continue to administer the parenteral nutrition, but at a lower rate. 
b. Remove the catheter from the affected site and place in another 
site. 
c. Remove the catheter from the affected site and replace proximal to the 
affected site. 
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d. None of the above 
 
8. Which electrolyte abnormalities are noted in the classic refeeding syndrome in 
humans? 
a. Hyperphosphatemia, hyperkalemia, hypermagnesemia 
b. Hyperphosphatemia, hypokalemia, hypomagnesemia 
c. Hypophosphatemia, hypokalemia, hypomagnesemia 
d. Hypophosphatemia, hyperkalemia, hypomagnesemia 
 
9. Phosphorus is utilized by the body to make: 
a. 2.3 DPG (2,3-diphosphoglycerate) 
b. ATP 
c. Cell membranes 
d. a and b 
e. a and c 
f. a, b, and c 
 
10. Cardiac arrhythmias, weakness, seizures, and ataxia are commonly associated 
with: 
a. Hypomagnesemia 
b. Hypophosphatemia 
c. Hypocalcemia 
d. All of the above  
e. None of the above 
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Chapter IV.  Effects of temperature and handling conditions on lipid 
emulsion stability in centrally administered veterinary parenteral 
nutrition (PN) admixtures  
 
 Parenteral nutrition is widely used in companion animal medicine, and 
standardized protocols for preparation of PN admixtures have improved safety of 
administration. However, the addition of lipids to PN admixtures still raises concerns 
about coalescence of lipid particles; such coalescence may result in the formation of 
particles that are sufficiently large to block small pulmonary blood vessels.  To reduce 
the risk of embolism associated with such coalescence, the FDA presently recommends 
administration of a single lipid-containing PN admixture preparation at room temperature 
for no longer than 24 hours.14 An informal survey of US and Canadian veterinary 
teaching hospitals conducted by the authors revealed that the FDA recommendation has 
been adopted by many institutions but that clinicians at other establishments administer 
PN solutions for 48 hours or longer.a 
 A lipid-containing solution is considered unsuitable for use when >0.4% of its 
lipid particles are larger than 5.0 μm in diameter.11,16,24,26,30,35,53,55,87,88 The typical 
diameter of chylomicrons in the bloodstream is 0.4 to 1.0 µm.  An abundance of large 
particles in the admixture puts an animal that is receiving PN at risk for development of 
lipid-induced pulmonary emboli, because the internal diameter of pulmonary capillaries 
is 4 to 9 µm.11,16,17,19,53,62,88    
 Lipid particles have a tendency to coalesce into larger particles.  The initial stages 
of lipid particle degradation include what is termed creaming, during which lipid particles 
rise to the surface of an emulsion, and flocculation, during which individual lipid 
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particles become associated with each other in groupings.  Both of these early stages of 
degradation can be reversed by agitation of solutions.  However, once the particles 
coalesce into larger particles, degradation is irreversible.   
  Because agitation of a lipid-containing admixture reverses lipid particle creaming 
and flocculation, agitation should slow the progression of coalescence and thereby 
prolong the period during which administration of such admixtures is considered safe. 
Similarly, use of an appropriately selected filter during delivery of the PN admixtures 
should be able to successfully remove coalesced lipid particles of embolic size, which 
would also potentially extend the duration of use of an admixture preparation. Results of 
previous research indicate that PN admixtures containing lipid emulsions can be kept for 
as long as one week at refrigeration temperatures (4°C) prior to their safe administration 
over a 24-hour period to humans, suggesting that keeping a PN admixture at refrigeration 
temperatures during administration should likewise prolong the preparation’s period of 
safe administration.25,27-29,30,31 
  In published retrospective studies76,77,89 of PN usage in dogs and cats, bags of PN 
solutions were either administered immediately or stored for as long as five days at 
refrigeration temperatures prior to administration. Although it was not always specifically 
stated in those reports, it appeared that a single bag of PN was not administered to a 
patient for >48 hours.  Mechanical complications (eg, catheter occlusions or 
dislodgements and development of thrombophlebitis) developed in 21%77 to 46%76 of 
treated animals. Hyperglycemia was another common complication ranging from 20%89 
to 75%76 of all patients, with cats seemingly more affected than dogs.  Other metabolic 
derangements detected in animals receiving PN were hypo- and hypernatremia, hyper- 
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and hypokalemia, hypo- and hypercalcemia, and hypo- and hyperphosphatemia.  
However, the proportions of the three study populations that developed these metabolic 
derangements were much less than those that developed hyperglycemia: only as many as 
10% of dogs and cats in one study,76 34% of cats in another study,77 and 11% of cats in a 
third study.89   There was an overall low rate of septic complications; in 2 studies, septic 
complications were not detected in cats or dogs76,89 and PN-associated sepsis developed 
in 6% of cats in another study.77  Lipemia was evident in 46% of cats and dogs76 and 13% 
to 24% of cats.77,89  No embolic respiratory complications were noted in any veterinary 
studies.   
   The purpose of the study reported here was to determine whether veterinary PN 
admixtures that are kept at room temperature (23°C) can be used for more than 48 hours 
after preparation without development of excessive lipid particle coalescence and 
whether lipid particle coalescence is prevented by filtration, refrigeration, or agitation of 
the preparations.  By use of TEM, the intent was to evaluate the change in lipid particle 
size distribution in bags of standard veterinary PN admixture over time at room 
temperature (23ºC); the goal was to determine whether prolonged duration of bag 
hanging (>24 hours) increased the embolic risk of PN administration due to the 
development of an unacceptable proportion of large lipid particles (ie, those >5 μm in 
diameter).  We were also interested to investigate whether the duration of safe 
administration of an admixture could be prolonged by physical manipulations of the PN 
admixture. If the duration of safe administration of each lipid-containing admixture can 
be extended (>24 hours), the result would be cost savings for clients.  At our institution, 
compounding fees and bag-administration set costs account for as much as 75% of the 
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daily cost of PN administration.  Prolonged use of admixture preparations would also be 
convenient for clinicians and pharmacists, especially over weekends and holidays when 
pharmacy services may be limited or unavailable.  Our hypotheses for the present study 
were that a standard lipid-containing veterinary PN admixture can be kept in a static 
position at room temperature for more than 48 hours prior to the development of an 
unacceptable proportion of large lipid particles (with their inherent increased risk of 
embolism) and that agitation, refrigeration, and filtration of an admixture preparation will 
delay increases in the size distribution of lipid particles that would be considered unsafe.    
 
Materials and Methods   
 Admixture preparation—Fifteen 2-L bagsb of PN admixture were prepared 
according to standard compounding protocols90 by a pharmacist at the University of 
Missouri-Columbia Veterinary Medical Teaching Hospital. Each bag contained 525 mL 
of 50% dextrose (1.7 kcal/mL),c 453 mL of 20% lipid emulsion (2 kcal/mL),d 840 mL of 
8.5% amino acids and electrolyte solution (1 g/11.76 mL),e and 5 mL of vitamin B 
complex.f  The admixture volume of each bag would support the resting energy 
requirement of a 10 kg adult dog for 96 hours as calculated by use of the following 
formula: (30 X weight [kg] ) + 70 kcal/day.  The reported size of the emulsified fat 
particles in the lipid emulsion was 0.5 µm.91 The admixture was typical of veterinary 
formulations, in that 50% of the non-protein metabolizable energy was available as lipid 
and 50% was available as dextrose (calculated osmolarity, 1,280 mosm/L).   
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Procedures—Each bag of PN admixture was attached to an intravenous (IV) fluid 
administration set and its contents were delivered by use of an IV fluid pumpg into a 
beaker to simulate IV administration to a patient.  The rate of administration was 16 
mL/h.  All PN solution delivered into the beaker was measured daily to verify the 
evacuation rate.   
 Bags of PN admixture were allocated to 1 of 5 groups; conditions of temperature 
and handling for the duration of the experiment differed for each group of bags. Group 1 
was composed of three bags of PN admixture that were each kept in a static position at 
refrigeration temperature (4°C).  Group 2 was composed of three bags of admixture that 
were each kept at room temperature (23°C) and were placed on a test tube orbital rotating 
deviceh; the device continuously agitated the admixtures in a circular motion (rotation 
speed, approx 360°/s [60 revolutions/min]).  Group 3 was composed of three bags of 
admixture that were each kept at room temperature and were placed on a test tube orbital 
rotating deviceh; the device  agitated the admixtures in a circular motion (rotation speed, 
approx 360°/s [60 revolutions/min]) for 5 minutes every 4 hours. Group 4 was composed 
of three bags of admixture that were each kept in a static position at room temperature; 
the admixture solution from each bag was passed through a 5-μm filteri placed at the 
approximate midpoint of the IV fluid administration set tubing.  At the end of the 96-hour 
collection period, two 10-mL samples of PN admixture were collected at a location distal 
to each filter, inoculated into trypticase-soy agar, and submitted for aerobic and anaerobic 
bacterial culture.  Group 5 (control group) was composed of three bags of PN admixture 
that were kept in a static position at room temperature.   
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Collection and assessment of PN admixture samples—A 1.0-mL sample was collected 
by use of aseptic technique from the most distal port on the IV fluid administration set 
tubing from each bag of PN admixture at 0, 24, 48, 72, and 96 hours.  Time zero samples 
were collected immediately from the distal port of the IV tubing after the tubing was 
primed with PN solution and before it was placed into the IV pump.  All samples were 
collected during a 3-week period.  During each week of that period, one of the three bags 
of PN admixture from each group (1 through 5) was compounded and underwent 
experimentation (including sample collections at the time points specified).    
 Immediately after collection, each sample of admixture was diluted 1:10 with 
physiologic saline (0.9% NaCl) solution.  The diluted sample was mixed 1:1 with 2% 
osmium tetroxide solution and allowed to stand for 15 minutes to allow fixation.  The 
osmium oxidized unsaturated bonds of fatty acids in the lipid particles, creating a heavy 
metal which stained the lipid membranes black.  Approximately 5 µL of the resulting 
mixture was placed on a 200-mesh carbon copper gridj and allowed to adhere to the grid 
for 5 minutes.  Excess solution was wicked off the grid, and the grid was washed 15 to 20 
times in sterile water to remove excess fixative and other precipitates that were not 
affixed to the grid.  The grid was then air dried prior to TEMk examination.     
 Via TEM, each grid was assessed for density of lipid particles and spatial 
distribution of particles (ie, clear separation or clumping of particles).  Particles that were 
closely associated with large deposits of background material were not recognized as 
separate particles by the image analysis software.  Thus, fields that were evaluated were 
those with high particle density and resolution.  Electron micrographs of 6 to 8 regions of 
each sample grid were obtained to capture images of at least 300 discrete lipid particles.  
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The overall goal was to obtain usable images of a total of 1,000 lipid particles from each 
group over the three week study period.   
 The TEM image negatives were digitized and analyzed by use of softwarel with 
image processing and analysis applications.m The software enumerated and measured 
diameters of particles in the electron micrographs.  Image processing was conducted by 
use of standard methods.92 Images were optimized by use of contrast adjustment prior to 
the application of bilevel thresholding and watershed segmentation to allow 
discrimination of separate lipid particles from background material.  Parameter filters 
were applied to remove particles <100 pixels and those that were not round in shape.   
 Radius and roundness were determined for each particle. Features were counted 
and included as particles if they were of a sufficient roundness. Roundness was calculated 
by use of an equation as follows: 
Roundness = 4[area]/π[maximum diameter]2 
A roundness of 1.0 indicates a perfect circle, and features with a roundness value <0.66 
were not evaluated. The diameter of a particle was determined by doubling the 
circumscribed radius determined for a perfect circle drawn around that particle (circle 
extended to the maximum borders of the particle).    
 
Statistical analysis— Particle diameters from each TEM micrograph were determined 
and tabulated by micrograph number (1, 2, 3, and so forth), bag number (1, 2, 3), time (0, 
24, 48, 72, or 96 hours), and group (1, 2, 3, 4, or 5) on a computerized data worksheet.n 
Treatment and sampling time effects were evaluated for mean, standard deviation (SD), 
median, and maximum values of lipid particle counts, and diameters.  Post-hoc Dunn 
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multiple comparison tests were used to determine significant differences in particle size 
among sample collection time points.   At each sample collection, the significance of 
effect of treatment (control conditions, refrigeration, intermittent agitation, continuous 
agitation, or filtration) was determined by use of a Kruskal-Wallis 1-way ANOVA on 
ranks.  The Holm-Sidak method was applied to determine whether there was a significant 
difference in the number of particles counted at each time point.  The Fisher exact test 
was used to determine whether the data within groups 1 through 4 were distinct from 
findings for control group 5 (ie, bags of PN admixture kept at room temperature without 
agitation or filtration).  χ2 analysis was used to determine the probability that 0.4% of 
particles were >5 µm in diameter in the control samples at 96 hours.   
  The number of electron micrographs evaluated for each admixture sample (six to 
eight) and the number of admixture bags within treatment groups (three) were based on a 
power analyses in which β was set to 0.8.  Frequency mean and variance estimates used 
in the power analysis were based on previously reported observations.93-95 Statistical 
analyses were conducted by use of commercially available software.o Significance was 
set at a value of p<0.05.  
 
Results  
 Among the initial (0 hour) samples collected from bags of each group, lipid 
particle diameter means, medians, and maximums did not differ significantly (p=0.65, p= 
0.82, and p=0.63, respectively); particles >5 μm in diameter were not observed. Of the 
3,208 particles in all groups evaluated at 0 hours, the largest particle diameter was 1.50 
μm.  This particle was present in a control group sample, was the largest particle detected 
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at any sample collection time point, and was approximately 6 times as large as the mean 
diameter of the control particles at 0 hours (0.26 μm; Table 12).   
 The total number of particles counted in the 96-hour samples obtained from the 
control group admixtures was 716.  If the proportion of large particles had reached 0.4%, 
2 or 3 particles >5 µm in diameter should have been detected.  Because no large particles 
were evident in control group samples collected at any time point, the proportion of large 
particles would have to have been <0.019%. The probability of not finding a large 
particle simply by random chance would be <0.1% (χ2;p<0.001) if the true frequency of 
large particles in the control bags at 96 hours was 0.4%. 
 Evaluation of particles from each group at each sample collection time point was 
successfully completed with the exception of 3 of the 75 sample collections. In each of 
those instances, particles were not evaluated because of poor quality TEM images in 
which lipid particles either were not evident or could not be distinguished from the 
background material despite examination of repeated sample preparations.  These poor 
images were derived from samples collected at 72 hours in the refrigeration group (1) 
during the third study week, at 72 hours in the intermittent agitation group (3) during the 
third study week, and at 96 hours in the filtration group (4) during the second study week.  
From each of those PN admixture bags, lipid particles from subsequent samples could be 
evaluated.   The cause of the poor image quality could not be identified.  
 Within a group, the number of particles counted in samples collected at each time 
point did not differ significantly, except for samples collected from group 2 bags that 
underwent continuous agitation. Within this group, more particles were detected at 96 
hours than at 0 hours (596 ± 108 particles vs 304 ± 272 particles; p=0.02). 
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 Compared with findings at 0 hours, lipid particle mean, median, and maximum 
diameters for each sample collection at 24, 48, 72, and 96 hours from the control bags 
(group 5) did not differ significantly (p=0.49, p=0.97, and p=0.14, respectively); those 
values for subsequent samples were also not significantly different from one another  
(Figure 2). Of the 5,256 total particles in control group samples evaluated at all time 
points, the largest particle diameter was 1.50 μm (at 0 hours). 
 Within each group (1 through 4), lipid particle mean, median, and maximum 
diameters at 24, 48, 72, and 96 hours were not significantly different from findings at 0 
hours and values did not differ significantly among sample collection time points. Mean, 
median, and maximum lipid particle diameters in samples from bags exposed to the 
experimental treatments were also not significantly different from paired observations in 
samples from bags of the control group at any sample collection time point (Table 12).  
Furthermore, at each sample collection time point, the mean, median, and maximum 
particle diameters among the treatment groups did not differ significantly. 
  Visual inspection of each lipid admixture was conducted daily when samples 
were collected for analysis.  Regardless of other experimental conditions, all bags kept in 
a static position had a visible cream layer at the admixture surface by 72 hours.  The PN 
solutions in the group 2 bags (continuously agitated) consistently had separated into 
distinct layers, developing a visible oil layer in the bag, the IV fluid administration set, 
and the cartridge loaded in the IV pump at 72 hours (Figure 3 and 4).  Culture of samples 
of the group 4 PN solutions collected at the end of the 96-hour collection period yielded 
no aerobic or anaerobic bacterial growth.   
Discussion 
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 For quantitative evaluation of lipid particles in aqueous emulsions, three 
techniques are generally accepted: light obscuration particle measurement, photon 
correlation spectroscopy (PCS), and transmission electron microscopy (TEM).93,94,96  
Transmission electron microscopy and PCS are equivalently accurate techniques and are 
superior to light obscuration particle measurement for particle size evaluation.94  When 
directly comparing the TEM and PCS techniques, particles <100 nm in diameter are more 
easily identified via TEM whereas particles <120 to 150 nm in diameter are difficult to 
detect via PCS.23  A potential limitation of all particle-sizing techniques is that sample 
sizes are exceedingly small and, therefore, could be construed as not representative of the 
entire admixture.24  Nevertheless, TEM imaging is considered an accurate and reliable 
means for identifying particle size in lipid emulsions.   
 For our purposes, TEM particle sizing was considered sufficient for identifying a 
distribution of lipid particle diameters in PN admixtures that would be associated with 
increased risk of embolism. Any emulsion is considered unsuitable for IV administration 
when the proportion of large particles (>5 μm in diameter) in an emulsion exceeds 0.4%.  
In the present study, initial statistical plans included categorizing particles as <5 μm in 
diameter versus ≥5 μm in diameter.   If the proportion of large particles had reached 0.4% 
in the control bags at the 96-hour time point, 21 particles >5 μm in diameter would have 
been observed. Despite counting and sizing 5,256 particles in 15 control bag samples 
during the entire study period, no particles were >5 μm in diameter in any control bag 
sample at any time point.  This result was unexpected, particularly in samples collected 
after the bags of admixture had been suspended and in use for 24 hours (the current 
recommended period of safe use of a PN preparation) and especially after 96 hours when 
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particle coalescence was anticipated to be the greatest.  Even after 96 hours, lipid 
particles in admixture samples collected from the IV fluid administration sets attached to 
control bags appeared to present no embolic risk. 
 In addition to finding an absence of particles >5 μm in diameter in the control 
bags at any sample collection time point, there was no difference in mean lipid particle 
diameters in control group samples collected at 0 and 96 hours.  This result was also 
unexpected because the lipids were anticipated to coalesce over time, causing a shift in 
the distribution of lipid particle diameters toward notably greater sizes.  These findings 
support the conclusion that, over time, the standard veterinary PN solutions used in our 
study that underwent no special temperature or handling manipulations did not develop a 
lipid particle diameter distribution associated with increased risk of embolism.   
 Results of the present study were in contrast to those of other studies26,97,98 of lipid 
particle size.  In 1 study,97 the percentage of large particles (1.6 to 25.4 µm in diameter) 
significantly increased between 0 and 72 hours both in samples kept at refrigeration 
temperatures and those kept at room temperature. That study did not include direct 
assessment of particle size, but relied on Coulter counter analysis of numbers and sizes of 
particles at various time points. In another study,26 admixtures containing lipid emulsion 
that were kept at room temperature developed particles with diameters >5 µm within 30 
hours, as determined via a dynamic light scatter technique. Breakdown of the admixture 
solutions was visible in both of those studies.  Another study98 in which PN admixtures 
were examined by use of a light extinction method revealed variation in particle sizes 
over time; with longer time intervals, greater particle sizes as well as visual precipitation 
of components were detected. The reason for variance of results of those studies from the 
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findings of the present investigation is not completely clear; however, it is important to 
note that in each of the previous studies, lipid particles were not directly viewed and 
measured to determine their diameters.     
 The findings of our study are not completely without precedent.  By use of 
scanning electron microscopy, investigators examined PN admixtures that had been 
stored at refrigeration temperatures for 28 days followed by administration at room 
temperature during a two day period and found that the mean diameter of lipid particles 
was not significantly increased from day 0 to day 30.31 In that study, mean initial particle 
diameter was 0.27 ± 0.08 µm and particle diameter on day 30 was 0.36 ± 0.11 µm; the 
largest particle detected was 2.74 µm.  Additionally, other studies30,25,27-29  in which PN 
solutions were evaluated after storage at refrigeration temperatures for as long as 28 days 
and then administered during a one to two day period at room temperature revealed that 
there were no significant changes in mean particle diameter over time nor did the 
proportion of lipid particles >2.0 µm in diameter exceed 0.4%. The techniques used in 
those studies included scanning electron microscopy, light microscopy, PCS, and 
computerized particle counting methods.  Results of other studies of PN admixture 
stability99-101 involving dynamic light scattering and light extinction methods of lipid 
particle examination indicated that, although there was a gradual increase in particle size 
over time, the proportion of large particles that could be associated with risk of embolism 
did not significantly increase after 30 hours at room temperature.  
 Variation in admixture mineral composition may account for the reported 
differences in lipid particle stability and may provide a reason for the long-term stability 
of the PN admixtures of the present study that were kept at room temperature. Typically, 
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the electrostatic charge (zeta potential) on the surface of lipid particles inhibits 
coalescence.16 This repulsive charge is bestowed on the lipid particles by the 
phospholipid surfactant in the lipid emulsion.  However, the presence and amount of ions 
in the PN admixture, especially the presence of divalent cations such as calcium2+, can 
alter these protective electrostatic charges.35,97,100  Additionally, phosphorus, a standard 
component of PN admixtures, can precipitate with calcium and result in lipid emulsion 
breakdown.35,98,101 The PN admixtures used in our study did not have calcium as a 
component, whereas most admixtures administered to humans (including those analyzed 
in other studies16,27,28,30,31,98-100) routinely contain calcium.  It is possible that calcium 
hastened the breakdown of PN admixtures in previous studies.  An interesting future 
investigation would involve the addition of calcium to the admixtures used in our study to 
determine whether calcium induces significant changes in lipid particle size over time.    
 Another intriguing finding of the present study was that after 72 hours, the PN 
admixture in the continuously agitated bags (group 2) had separated into distinct layers 
within the bag and the chambers of the infusion set and IV tubing.  The uppermost layer 
appeared to be an oil layer, indicating coalescence of lipid particles.  This is similar to the 
finding of an investigation97 by Bettner and Stennett, where rings of oil began forming by 
48 hours and progressed to free floating oil layers by one week in both refrigerated and 
room temperature admixtures.   In our study, no large lipid particles were detected via 
TEM examination in the PN admixtures in group 2 bags, despite the presence of an oil 
layer.  Comparison of mean and maximum particle sizes over time in the continuously 
agitated bags and control bags did not indicate any difference in particle size distribution.   
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 Although it is unclear why continuous agitation of group 2 bags in our study led 
to breakdown of the emulsion without evidence of large lipid particles in samples 
collected from the distal IV port of the administration sets, we support recommendations 
not to administer such separated emulsions to patients to avoid pulmonary 
embolism.11,14,35 Agitation may have disrupted the surfactant layer in the lipid emulsion 
and nullified the repulsive electrostatic charges on the lipid particles, thereby promoting 
coalescence.  Alternatively, agitation may have overwhelmed the repulsive forces of the 
particles, leading to collision between and eventual coalescence of lipid particles into a 
visible oil layer. Because of lower density, coalesced particles may have essentially 
floated away from the outflow of smaller more dense intact particles in solution to create 
a poorly mixed oil layer.  If this were the case, the less-dense large particles or oil layer 
may have been more likely to separate from the smaller more-dense particles in the IV 
fluid administration set components where the admixture was held relatively static for 
short periods of time.  Our assumption is that the smaller more-dense particles would 
have continued to move through the IV fluid administration set and were collected in 
samples from the distal port, whereas the oil layer remained behind.  This explanation 
could be tested by mixing the contents of the bag daily before sample collection and also 
by collecting samples directly from the bag rather than from the IV administration set 
tubing and pump; those samples could then be examined via TEM to ascertain whether 
large particles were present.    
 In the present study, the creaming that developed in the PN bags in groups 1, 4, 
and 5 after 72 hours was expected and consistent with previous reports of changes in lipid 
admixtures that remained static.11,14,16,35,55,97 Because creaming does not indicate 
 70
coalescence of lipid particles, it was expected that the lipid particles examined 
microscopically would not exceed the 5-µm-diameter cut-off point in any of the samples 
from these groups.  It is widely held that gentle agitation can reblend mixtures that have a 
cream layer without safety concerns regarding their administration to patients.   
 The finding of no aerobic or anaerobic bacterial growth in cultures of samples 
collected from admixtures that were held static at room temperature in our study is 
consistent with previous reports that bacterial growth in properly prepared and handled 
PN admixtures is rare and usually results from patient or hospital-related 
contamination.11,35,51,62  Therefore, taking into account our findings regarding bacterial 
contamination, microscopic lipid particle size, and the visual appearance of admixtures, 
we conclude that properly compounded PN admixtures of the type used in the present 
study that are kept static at room temperature are unlikely to develop large lipid particles 
with an inherent risk of embolism when administered for longer than 48 hours, without 
the need for other interventions.     
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Chapter 5.  Future directions. 
 
The termination of this research supports the conclusion that lipid particles in the 
veterinary parenteral nutrition (PN) admixtures studied do not coalesce into pro-embolic 
particles over a 96-hour period.  Obviously, one can then conclude that parenteral 
nutritional admixtures formulated as described in our study do not have to be discarded 
within 24 hours to protect a patient from lipid-particle-induced pulmonary embolism.  
However, the question still remains as to how long a single veterinary PN admixture as 
detailed in this thesis research can be used in a patient before simply not being 
nutritionally viable.  Additionally, it is not clear whether the addition of other 
components to the admixture would alter the rate of lipid particle coalescence.     
 As presented in the introduction to this thesis research (Chapter 1), nutritional 
concerns related to nutrient degradation (especially vitamins) is very important.  Thus, a 
study conducted in a similar fashion to this original research but with routine daily PN 
sampling for vitamin concentrations would be a logical next step.  If it could be proved 
that B vitamins as well as other commonly used veterinary vitamin additives to PN are 
viable for greater than 48 hours, one could state that it is definitively recommended to 
utilize the veterinary PN solutions used in the study for 48 hours or more.  This would in 
turn alleviate any concerns related to both nutrition and safety in the admixtures. 
 An additional point of future research centers around the varying results found in 
lipid particle size with different particle sizing techniques.  As discussed extensively in 
Chapter 4, there is a large amount of variability in the results of similar studies looking at 
lipid particle sizes over time.  Some studies26,97,98 documented the development of pro-
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embolic lipid particle sizes over shorter time frames than in our study while other 
studies27-31,99-101 had similar findings to our work.   
 The first logical step to explore this inconsistency more closely would be to 
compare lipid particle diameters in PN admixtures created as detailed in our study using 
different particle sizing techniques.  For example, a single bag of PN at time 0 could be 
examined simultaneously using the transmission electron microscope (TEM) as well as 
light obscuration particle sizing and Coulter counting.  The results could then be 
compared to determine if the particle sizing technique altered the particle diameters 
recognized and enumerated.   
 Two important things could come from comparing particle sizing techniques.  
First, it would be intriguing to see if the results noted in this original study could be 
reproduced by more than one particle sizing technique.  If the results could not be 
reproduced, it would raise important questions about the validity of each particle sizing 
technique.  If the results could be reproduced, it would strongly support the fact that there 
is another factor differing between studies -- more than simply the particle sizing 
technique -- that has led to the discrepancies between some of the published literature and 
our study.   
 The discussion section of Chapter IV details our hypothesis that it was likely the 
additional components added to the PN admixtures -- calcium and other charged ions – 
which lead to the breakdown of the surfactant layer and eventual coalescence of lipid 
particles in other studies.  In order to evaluate this further, a logical first step would be to 
add calcium to the standard veterinary PN admixture used in this project and repeat the 
same study design using one group of PN admixture with calcium and one group without 
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the addition of calcium.  The same sampling and sizing techniques could be applied to 
these two groups to determine if there were any significant differences between PN 
admixtures with and without calcium.  The results of such a study would provide 
important information regarding the role of cations such as calcium in the stability of PN 
admixtures. 
 Despite the girth of information available on PN in the human medical field, close 
inspection still reveals gaps in this knowledge which prompt questions that need to be 
answered.  Our research project has contributed to one such void regarding lipid particle 
degradation over time.  Still other areas requiring more knowledge include the possible 
patient-related contraindications for lipid administration (pro-inflammatory conditions, 
sepsis, etc) and whether medium chain triglycerides may be better PN lipid sources than 
long chain triglycerides.  The future is ripe for further exploration into the field of lipids 
and PN for both veterinary and human researchers.    
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Appendix 1.  Expanded statistical data analysis 
 
 
Summary of Statistical Analyses 
 
1. None of the particles in any bag of any group at any time were 5μ or larger. 
2. The single largest particle identified was 1.496μ (Group 5, Bag 3, Day 0). 
3. The largest average particle size was 0.373μ (Group 5, Bag 2, Day 4). 
4. The largest median particle size was 0.305μ (Group 5, Bag 2, Day 4). 
5. The following tables contain the descriptive statistics for each bag, each day, each 
 time: 
 
Bag 
Identification* 
# 
Particles 
Counted 
Average  
Particle 
Size (μ) 
Standard 
Deviation
Maximum Minimum Median 
1,1,0 159 0.258 0.126 0.877 0.110 0.220 
1,2,0 224 0.247 0.100 0.997 0.118 0.224 
1,3,0 104 0.286 0.148 1.109 0.112 0.246 
1,1,1 276 0.234 0.087 0.804 0.115 0.218 
1,2,1 111 0.262 0.103 0.539 0.015 0.242 
1,3,1 384 0.241 0.091 0.645 0.112 0.226 
1,1,2 393 0.236 0.100 0.804 0.084 0.215 
1,2,2 642 0.241 0.098 1.012 0.106 0.221 
1,3,2 110 0.256 0.109 0.662 0.108 0.239 
1,1,3 66 0.280 0.152 0.674 0.007 0.237 
1,2,3 315 0.254 0.108 0.848 0.093 0.222 
1,3,3 -- -- -- -- -- -- 
1,1,4 259 0.264 0.109 0.007 0.903 0.110 
1,2,4 248 0.253 0.104 0.749 0.172 0.188 
1,3,4 768 0.222 0.091 0.839 0.109 0.202 
*Bag Identification: a,b,c    where a = Group Number; b = Bag Number;  
c = Day of Sample 
Bag Identification 1,1,0 would be for Group 1; Bag 1; Day 0  
Bag Identification 1,2,2 would be for Group 1; Bag 2; Day 2 
Bag 
Identification 
# 
Particles 
Counted 
Average  
Particle 
Size (μ) 
Standard 
Deviation
Maximum Minimum Median 
2,1,0 132 0.244 0.124 1.029 0.109 0.200 
2,2,0 162 0.259 0.105 0.761 0.116 0.244 
2,3,0 618 0.248 0.103 0.639 0.007 0.235 
2,1,1 194 0.243 0.099 0.823 0.110 0.219 
2,2,1 81 0.289 0.140 1.118 0.129 0.241 
2,3,1 267 0.239 0.088 0.623 0.114 0.223 
2,1,2 307 0.230 0.099 0.660 0.082 0.213 
2,2,2 136 0.262 0.102 0.577 0.117 0.235 
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2,3,2 368 0.242 0.098 0.731 0.109 0.219 
2,1,3 189 0.228 0.138 0.962 0.007 0.200 
2,2,3 345 0.223 0.078 0.610 0.098 0.209 
2,3,3 234 0.248 0.099 0.785 0.110 0.226 
2,1,4 472 0.233 0.101 0.958 0.108 0.210 
2,2,4 670 0.225 0.082 0.690 0.107 0.214 
2,3,4 645 0.216 0.088 1.066 0.108 0.200 
 
Bag 
Identification 
# 
Particles 
Counted 
Average  
Particle 
Size (μ) 
Standard 
Deviation
Maximum Minimum Median 
3,1,0 142 0.271 0.115 1.075 0.117 0.252 
3,2,0 216 0.271 0.128 0.840 0.113 0.234 
3,3,0 101 0.239 0.123 0.688 0.007 0.212 
3,1,1 319 0.252 0.100 0.641 0.007 0.242 
3,2,1 185 0.262 0.112 0.924 0.111 0.235 
3,3,1 882 0.244 0.098 1.151 0.111 0.230 
3,1,2 246 0.233 0.111 0.996 0.007 0.219 
3,2,2 737 0.234 0.086 0.549 0.105 0.217 
3,3,2 100 0.259 0.134 0.884 0.115 0.223 
3,1,3 143 0.229 0.132 0.817 0.007 0.197 
3,2,3 357 0.252 0.099 0.922 0.114 0.234 
3,3,3 -- -- -- -- -- -- 
3,1,4 307 0.243 0.099 0.821 0.106 0.222 
3,2,4 98 0.282 0.117 0.636 0.128 0.256 
3,3,4 144 0.262 0.103 0.635 0.102 0.241 
 
Bag 
Identification 
# 
Particles 
Counted 
Average  
Particle 
Size (μ) 
Standard 
Deviation
Maximum Minimum Median 
4,1,0 157 0.241 0.081 0.533 0.118 0.233 
4,2,0 84 0.275 0.125 0.751 0.025 0.263 
4,3,0 150 0.248 0.110 1.053 0.118 0.227 
4,1,1 1183 0.223 0.083 0.755 0.007 0.211 
4,2,1 99 0.238 0.126 0.981 0.007 0.219 
4,3,1 234 0.264 0.107 0.723 0.113 0.241 
4,1,2 364 0.231 0.096 0.702 0.085 0.210 
4,2,2 232 0.232 0.085 0.583 0.105 0.218 
4,3,2 188 0.241 0.094 0.617 0.108 0.216 
4,1,3 149 0.234 0.116 0.706 0.007 0.226 
4,2,3 183 0.241 0.104 0.556 0.015 0.221 
4,3,3 50 0.280 0.111 0.530 0.115 0.267 
4,1,4 271 0.284 0.137 1.424 0.110 0.263 
4,2,4 -- -- -- -- -- -- 
4,3,4 289 0.250 0.092 0.808 0.109 0.231 
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Bag 
Identification 
# 
Particles 
Counted 
Average  
Particle 
Size (μ) 
Standard 
Deviation
Maximum Minimum Median 
5,1,0 660 0.250 0.090 0.900 0.109 0.233 
5,2,0 103 0.265 0.111 0.760 0.117 0.237 
5,3,0 196 0.310 0.206 1.496 0.113 0.249 
5,1,1 1455 0.215 0.081 0.648 0.021 0.204 
5,2,1 352 0.264 0.102 0.710 0.114 0.241 
5,3,1 210 0.272 0.123 0.956 0.112 0.242 
5,1,2 44 0.271 0.141 0.837 0.117 0.230 
5,2,2 563 0.253 0.094 0.754 0.109 0.235 
5,3,2 175 0.243 0.127 0.692 0.114 0.251 
5,1,3 44 0.271 0.140 0.837 0.117 0.226 
5,2,3 563 0.253 0.094 0.754 0.109 0.235 
5,3,3 175 0.279 0.126 0.691 0.113 0.251 
5,1,4 485 0.243 0.100 1.088 0.111 0.226 
5,2,4 10 0.373 0.241 0.934 0.148 0.305 
5,3,4 221 0.255 0.102 0.768 0.110 0.233 
 
 
6. Comparative Statistics (Repeated Measures Analysis of Variance or Friedman 
Repeated Measures Analysis of Variance on Ranks) 
 a. Group 1, Comparison of particle diameter among times (0, 1, 2, 3, and 4 days):   
  i.   Comparing means for each time:  p = 0.495 
  ii.  Comparing medians for each time:  p = 0.968 
  iii. Comparing maximums for each time:  p = 0.143 
  iv. Comparing number of particles counted for each time:  p = 0.463 
 
 b. Group 2, Comparison among times (0, 1, 2, 3, and 4 days): 
  i.   Comparing means for each time:  p = 0.148 
  ii.  Comparing medians for each time:  p = .356 
  iii. Comparing maximums for each time: p = 0.536 
  iv. Comparing number of particles counted for each time:  p = 0.024 
 (Time 4 significantly greater than time 1; Multiple Comparison Test 
 was Holm-Sidak Method) 
 
 c. Group 3, Comparison among times (0, 1, 2, 3, and 4 days): 
  i.   Comparing means for each time:  p = 0.355 
  ii.  Comparing medians for each time:  p = .344 
  iii. Comparing maximums for each time: p = 0.530 
  iv. Comparing number of particles counted for each time:  p = 0.474 
 
 d. Group 4, Comparison among times (0, 1, 2, 3, and 4 days): 
  i.   Comparing means for each time:  p = 0.226 
  ii.  Comparing medians for each time:  p = .125 
  iii. Comparing maximums for each time: p = 0.109 
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  iv. Comparing number of particles counted for each time:  p = 0.130 
 
 e. Group 5, Comparison among times (0, 1, 2, 3, and 4 days): 
  i.   Comparing means for each time:   p = 0.910 
  ii.  Comparing medians for each time:  p = 0.979 
  iii. Comparing maximums for each time:  p = 0.294 
  iv. Comparing number of particles counted for each time:  p = 0.668 
 
7. Comparative Statistics (Analysis of Variance or Kruskal Wallis Analysis of Variance 
on Ranks) 
 a. Time 0, Comparison of particle diameters among groups (1,2,3,4,5) 
  i.   Comparing Means for each group: p = 0.648 
  ii.  Comparing Medians for each group: p = 0.822 
  iii. Comparing Maximum for each group: p = 0.627 
  iv. Comparing number of particles counted for each group: p = 0.693 
 
 b. Time 1, Comparison among groups (1,2,3,4,5) 
  i.   Comparing means for each group: p = 0.922 
  ii.  Comparing medians for each group: p = 0.890 
  iii. Comparing maximums for each group: p = 0.681 
  iv. Comparing number of particles counted for each group: p = 0.671 
 
 c. Time 2, Comparison among groups (1,2,3,4,5) 
  i.   Comparing means for each group: p = 0.318 
  ii.  Comparing medians for each group: 0.084  (power = 0.368) 
  iii. Comparing maximums for each group: p = 0.384 
  iv. Comparing number of particles counted for each group: p = 0.938 
 
 d. Time 3, comparison among groups (1,2,3,4,5) 
  i.   Comparing means for each group: p = 0.329 
  ii.  Comparing medians for each group: p = 0.443 
  iii. Comparing maximums for each group: p = 0.212 (power = 0.167) 
  iv. Comparing number of particles counted for each group: p = 0.540 
 
 e. Time 4, comparison among groups (1,2,3,4,5) 
  i.   Comparing means for each group: p = 0.204 
  ii.  Comparing medians for each group: p = 0.058, power = 0.463 
  iii. Comparing maximums for each group: p = 0.263 (power = 0.132) 
  iv. Comparing number of particles counted for each group: p = 0.151 
 (power = 0.238) 
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Appendix 2.  Expanded methods for evaluation of lipid particles using 
Adobe Photoshop with the Fovea pro application 
 
 
TEM image negatives were digitized and analyzed using Adobe Photoshopl with the 
Fovea Pro applicationm.  The software was used to enumerate and measure the diameters 
of particles in the micrographs.  The image processing was conducted using a 
compilation of various standard methods described for image processing; the exact steps 
will be described in the following text.   
1. The photoshop images were viewed using grayscale 8 bit.  
2. Calibrate magnification was selected from the “measure global” menu.  The 
calibration was set to micrometers for the evaluation of all micrographs.   
3. The original photoshop image file was selected to include only the area with well-
differentiated lipid particles.  This allowed the user to delete obvious regions where 
the lipids were conglomerated into large masses and also allowed one to disregard the 
label present on the right lateral aspect of each micrograph.  The resulting selected 
area from each micrograph was then pasted into a new photoshop file that could be 
manipulated freely.   
4. Under the “image” menu, “adjustments” and then “levels” were selected.  This 
allowed the user to manually manipulate the grayscale and the whiteness bars.  The 
goal was to create the greatest contrast possible between the lipid particles and both 
the background and the other adjacent lipid particles while not losing any of the 
borders of the actual lipid particles themselves.   
5. Under the “filter” menu, “threshold” and then “bilevel thresholding” was selected.  
This option allowed the Fovea Pro application to essentially assign the structures in 
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the micrograph to be black or white.  Again, the application allowed for manual 
adjustment to ensure that all lipid particles were black and all background material 
was white.  From this point on, all manipulations involved only the sections that were 
identified as black, referred to as features. 
6. Under the “filter” menu, “watershed segmentation” was selected.  This application 
forced the Fovea Pro application to create differentiation between the lipid particles 
that were found directly adjacent to each other.     
7. Under the “filter” menu, “measure features” and then “reject features” was selected.  
This allowed rejection of all features that were clearly remnants of background 
material and/or improperly segmented portions of particles.  We rejected any features 
less than 1000 µm.   
8. Under the “filter” menu, “measure features” and then “accept features” was selected.  
The parameter selected was “shape” followed more specifically by “roundness.”  This 
directed the software to accept features that were clearly not linear or polygons.   
9. Under the “filter” menu, select “measure all features.”  This created raw data from 
each feature remaining.  The raw data was then imported into an Exceln spreadsheet. 
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Appendix 3.  Expanded description of radius and roundness 
determination for each lipid particle 
 
Radius and roundness was determined for each lipid particle captured on an 
electron micrograph.  For all determinations of radius, the circumscribed radius was used 
in this study.  The circumscribed radius is determined when a circle is drawn around the 
MAXIMUM dimensions of the polygon.  This is in contrast to the inscribed radius which 
is determined from the circle drawn inside the dimensions of the polygon and which may 
not account for the maximum diameter of a particle.  We elected to utilize the 
circumscribed radius in order to ensure that we were measuring the maximum diameter 
of all lipid particles.  When dealing with lipid particles in this study, it was better to 
overestimate the size of the lipid particles rather than underestimate the size and deem a 
admixture safe that actually has a quantity of lipid particles present that could potentially 
lead to pulmonary embolism.    
Features found on the electron micrographs were counted and included as lipid 
particles if they were of a sufficient roundness, ie. a roundness factor of greater than or 
equal to 0.66 (with 1.0 being a perfect circle).  The exclusion point of 0.66 for the 
roundness measurement was determined by manual visual assessment of which particles 
appeared to be round lipid particles and which were not.  In order to determine the 
validity of using 0.66 as an exclusion point, manual assessment was made of 543 features 
using the 0.66 cutoff (all particles with roundness values of less than 0.66 were 
considered to not be particles and those with roundness values greater than 0.66 were 
determined to be round lipid particles).  The 543 features were evaluated from 
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micrographs from Group #1, time 72 hrs; group 4, time 96 hrs; group 5, time 72 hrs; 
group 3, time 0 hrs; group 1, time 96 hrs; and group 3, time 0 hrs.   
When the features were examined, 14 features that were clearly not round lipid 
particles were falsely included in the “round” dataset from the 543 examined (2.6%) and 
13 true round lipid particles (2.4%) were erroneously excluded from the “round” dataset 
using this criterion.  Therefore, although the cut-off is subjective, it was deemed to be 
valid for our study based on the similar low rate of falsely excluded and included 
particles. 
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Appendix 4. Expanded discussion of study limitations 
 
In our study, several limitations were included with the imaging methods above and 
beyond the small samples analyzed.  First, although a great attempt was made to scan the 
grid and select representative samples for micrographs, the lipid particles were not 
always evenly distributed across the grid.  Therefore, it was always a possibility that there 
were regions in which larger lipid particles were located that were not discovered by the 
investigator.  When such a small percentage of total particles is significant (0.4%), even 
missing one or two particles larger than 5 µm could be significant.  However, this 
limitation was uniform for every sample analyzed during the course of the entire 
experiment.     
Secondly, great reliance was placed on the Adobe Photoshop and the Fovea Pro 
applications to be able to distinguish between lipid particles even when the borders were 
in apposition or there was a large amount of background material that partially obscured 
the borders of the lipid particles.  In the majority of cases, the computer was able to 
successfully differentiate between lipid particles; however, there were still cases for each 
sample where adjacent particles were not separated but were lumped together by the 
computer applications, leading to miscounting and sizing of particles.  Some of these 
‘multi-particles’ may have resulted in erroneously large particle diameters, but in other 
cases they were excluded from the dataset due to their polygonal rather than round shape.     
Thirdly, there were three occasions in which no lipid particles could be distinguished 
on the sampling grids at various time points despite repeated sample collection and grid 
preparations.  These were group 1 at 48 hours during the 3rd sampling week; group 3 at 
48 hours during the 3rd sampling week; and group 4 at 72 hours during the 2nd sampling 
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week.  In each case, this inability to distinguish particles was due to the vast amount of 
background material that completely encompassed and obscured the particles.  While it is 
possible that large lipid particles were present in those instances and simply were not 
being seen and counted, it seems unlikely in light of the distribution of small lipid 
particles seen on the following sampling day in each case.  Additionally, at the same time 
point during the other two collection periods associated with that group, lipid particles 
were distinguished and were found to be much smaller than 5 µm.     
However, despite these limitations, the data gathered from this study is deemed to 
be both valid and significant.  See chapter IV for a discussion of the findings and 
conclusions that can be drawn from those findings.     
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Appendix 5. TABLES 
 
Table 1.  A comparison of veterinary total parenteral nutrition and partial parenteral 
nutrition.   
 
Total Parenteral Nutrition (TPN) Partial Parenteral Nutrition (PPN) 
Marked hypertonicity (850-2000 
mOsm/L) 
Mild hypertonicity (avg. 500 – 600 
mOsm/L) 
Supply total patient energy needs Usually do not supply all patient 
energy                                      
needs 
Central venous administration required Peripheral venous administration 
possible 
May be deficient in total vitamin and 
mineral needs depending on formulation 
Typically deficient in vitamin and 
mineral needs 
 
 
 
 
 
 
 
 
 
Indications for PPN41
1.  Short term nutritional support in non-
debilitated patients (no signs of malnutrition) 
 
2.  Patients in which central venous 
catheterization is contraindicated or impossible 
to perform 
 
3.  Supplemental nutrition to enteral feeding in 
order to provide complete nutrition to the 
patient 
Table 2. Indications for PPN 
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Table 4.  Guidelines for the initiation of nutritional support.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Indications for TPN42
1.  In patients unable to enterally absorb 
nutrients for more than 3-5 days, especially 
with apparent signs of malnutrition 
Examples – massive small intestinal 
resections, chronic/intractable vomiting, 
severe diarrhea 
 
2.  Severe prolonged pancreatitis when 
enteral feeding tubes (especially 
jejunostomy tubes) are not an option 
 
3.  Severe malnutrition with a non-
functional gastrointestinal tract 
 
4.  Intolerance to enteral tube placement 
(including anesthesia to place the feeding 
tube) or force feeding 
 
Guidelines for the initiation of nutritional support65
 
1.  Acute weight loss of 5% or chronic weight loss of 10% or more 
 
2.  Anorexia or inappetence for three or more days, especially in 
patients already receiving intravenous fluids.* 
 
3.  Indications of decreased protein intake such as cachexia, poor 
body condition, overall weakness, and non-healing wound(s) 
 
 
*As discussed in the text, it is appropriate to initiate nutritional 
support sooner than three days, especially if other physical 
examination or historical parameters indicate the need to do so.   
e Table 3. Indications for TPN 
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Table 5.  Technical guidelines for the administration of PN.   
 
Technical Guidelines for the Administration of Parenteral Nutrition (PN) 
1. Place any intravenous (IV) line (central or peripheral) in aseptic fashion 
a. Clean and prepare skin as if for surgery 
b. Wear sterile gloves when placing and handling IV catheter, IV line, PN 
bag, etc.  
c. Keep catheter, IV tubing, PN bag sterile 
 
2. Cover all connections between IV catheter, IV lines, and PN bag with sterile 
dressing to prevent bacterial or fungal contamination 
 
3. Do not disconnect the patient from the bag of PN unless it is to attach a new bag 
of PN.  Transport patient at all times -- including outdoors -- with IV lines and PN 
bag attached. 
 
4. Do not use the IV catheter through which PN is being administered for any other 
solution – no drugs, fluids, etc through the PN tubing or IV ports 
 
5. Minimize handling of the PN system!! 
6. Place any IV (central or peripheral) in aseptic fashion 
a. Clean and prepare skin as if for surgery 
b. Wear sterile gloves when placing and handling IV catheter, IV line, PN 
bag, etc.  
c. Keep catheter, IV tubing, PN bag sterile 
 
7. Cover all connections between IV catheter, IV lines, and PN bag with sterile 
dressing to prevent bacterial or fungal contamination 
 
8. Do not disconnect the patient from the bag of PN unless it is to attach a new bag 
of PN.  Transport patient at all times -- including outdoors -- with IV lines and PN 
bag attached. 
 
9. Do not use the IV catheter through which PN is being administered for any other 
solution – no drugs, fluids, etc through the PN tubing or IV ports 
 
10. Minimize handling of the PN system!! 
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Table 6.  Sample calculation of TPN for a 10 kg dog that is suffering from 
pancreatitis.   
 
Step I: Calculate the 
BER 
30 (10kg) +70 = 370 kcal/day 
Step II: Calculate the 
TER 
In this case we will use an illness factor of 1.0. 
TER= 370 kcal/day 
Step III: Determine daily 
protein requirement 
4 g/100 TER kcal/day × 370 kcal/day  = 14.8 g of 
protein/day 
 
Step IV: Determine the 
volume of nutrient 
solutions required --    
 
Dextrose 
Patient will receive 60% of its daily energy requirement as 
dextrose 
 
0.60 × TER  
= 0.60 × 370 kcal/day  
= 222 kcal/day as dextrose 
 
222 kcal/day ÷ 1.7 kcal/mL of 50% dextrose 
= 130.5 mL/day (rounded to 131 mL/day) of 50% dextrose 
  
Lipids Patient will receive 40% of its daily energy requirement as 
lipid 
 
0.40 × TER 
= 0.40 × 370 kcal/day 
= 148 kcal/day as lipids 
 
148 kcal/day ÷ 2 kcal/mL of 20% lipid solution 
= 74 mL/day of 20% lipid solution  
 
Amino Acids 14.8 g of protein/day ÷ 85 mg/mL of 8.5% amino acid 
solution 
= 174.1 mL/day (rounded to 174 mL/day) of amino acids  
         
Step V: Determine the 
total volume and hourly 
rate of TPN solution 
administration 
 
131 mL + 74 mL + 174 mL =  379 mL/day of TPN solution 
379 mL/day ÷ 24 hours = 15.8 mL/hour of TPN solution 
Step VI: Determine the 
daily vitamin 
requirements  
 
Vitamin K: 0.5 mg/kg ×10 kg = 5 mg vitamin K SQ given 
once weekly if needed 
 
Possibly supplementation with vitamin B 
For example: 
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370 kcal/day  ÷ 1 mL B complex/1000 kcal = 0.37 mL 
 
 
Step VII: Administer the 
TPN 
Day 1 – administer 1/3 of calculated requirement 
= 1/3 (379 mL/day +  0.37 mL of B vitamins/day) ÷ 24 hrs 
= 5.4 mL/hr 
 
Day 2 – administer 2/3 of calculated requirement 
= 2/3 (379 mL/day + 0.37 mL B vitamins/day) ÷ 24 hrs 
= 10.6 mL/hr 
 
Day 3+  Administer the full calculated requirement plus 0.07 
mL B vitamins per day 
= 379 mL/day + 5 mL B vitamins/day ÷ 24 hrs 
= 16 mL/hr 
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Table 7.  Sample calculation of PPN for a 10 kg dog with a gastrointestinal 
foreign body that is going to surgery the next day for foreign body removal and 
enteral feeding tube placement. 
 
 
 
Step I: Calculate the 
TER 
BER= 30 (10kg) +70 = 370 kcal/day 
In this case we will use an illness factor of 1.0. 
TER= 370 kcal/day 
Step II: Calculate the 
PER 
PER = TER × 50% 
= 370 kcal/day × 0.50 = 185 kcal/day 
 
Step III: Determine 
calorie sources for this 
patient 
 
A 10 kg dog will receive 1/3 of PER from protein, dextrose, 
and lipid sources. 
185 kcal/day × 0.33 = 61.3 kcal/day 
 
Therefore, 61.3 kcal/day from amino acids, dextrose and lipids 
respectively.   
Step IV: Determine the 
volume of nutrient 
solutions required –  
Dextrose 
 
61.3 kcal/day ÷ 0.17 kcal/mL of 5% dextrose 
= 360.5 mL/day (rounded to 361 mL/day) of 5% dextrose 
  
  
Lipids 
 
61.3 kcal/day ÷ 2 kcal/mL of 20% lipid solution 
= 30.6 mL/day (rounded to 31 mL/day) of 20% lipid solution 
 
 
Amino Acids 
 
61.3 kcal/day ÷ 0.34 kcal/mL of 8.5% amino acid solution 
= 180.2 mL/day (rounded to 180 mL/day) of amino acids  
         
Step V: Determine the 
total volume and hourly 
rate of PPN solution 
administration 
 
360 mL + 31 mL + 180 mL = 571 mL/day of PPN solution 
(Note: This volume is greater than the daily maintenance water 
requirement estimated for a 10 kg dog) 
 
676 mL/day ÷ 24 hours = 23.7 mL/hour of PPN solution 
Step VI: Determine the 
daily vitamin 
requirements  
 
Vitamin K: not needed in this patient because will be receiving 
enteral nutrition within the next 24 hours 
 
Vitamin B: possibly consider supplementing vitamin B 
For example --  
185 kcal/day (PER) ÷ 1 mL B complex/1000 kcal = 0.19 mL  
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Step VII: Administer the 
PPN 
 
Give at full calculated rate immediately 
 
This patient will receive 24 mL/hr of PPN right away. 
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Table 9. Recommended potassium supplementation for hypokalemic patients.85 
 
Patient’s measured K+ 
level 
Recommended volume 
KCl added 1 L of fluids 
Maximum rate of K+ 
administration 
   <2.0 mmol/L 80 mEq/L 6 mL/kg/hr 
2.0-2.5 mmol/L 60 mEq/L 8 mL/kg/hr 
2.5-3.0 mmol/L 40 mEq/L 12 mL/kg/hr 
3.1-3.5 mmol/L 30 mEq/L 17 mL/kg/hr 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tips to reduce infection: 
1. Aseptic preparation of the PN solution 
2. Sterile catheter placement and line 
handling 
3. Changing/replacing intravenous lines 
only as needed  
4. Intravenous port/line dedicated to PN 
5. Small number of individuals limited to 
handling the PN line 
 
Table 8. A review of safety tips for administering parenteral nutrition (PN). 
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Table 10.  Blank TPN worksheet. 
 
Step I: Calculate the 
BER 
30 ( __ kg) +70 = ____ kcal/day 
Step II: Calculate the 
TER 
In this case we will use an illness factor of 1.0. 
TER= illness factor × BER = ______ kcal/day 
Step III: Determine daily 
protein requirement 
Select protein requirement × _____ kcal/day  = ___ g of 
protein/day 
 
Step IV: Determine the 
volume of nutrient 
solutions required --    
 
Dextrose 
Patient will receive ____% of its daily energy requirement as 
dextrose 
 
_____% × TER  
= ______ kcal/day as dextrose 
 
_____ kcal/day dextrose ÷ 1.7 kcal/mL of 50% dextrose 
= ______ mL/day of 50% dextrose 
  
Lipids Patient will receive (100- ___)% of its daily energy 
requirement as lipid 
 
____% × TER 
= _____ kcal/day as lipids 
 
_____ kcal/day ÷ 2 kcal/mL of 20% lipid solution 
= ____ mL/day of 20% lipid solution  
 
Amino Acids ____ g of protein/day ÷ 85 mg/mL of 8.5% amino acid 
solution 
= _____ mL/day of amino acids  
         
Step V: Determine the 
total volume and hourly 
rate of TPN solution 
administration 
 
mL of dextrose + mL of lipids + mL of amino acids  
=  ______ mL/day of TPN solution 
_____ mL/day ÷ 24 hours = _____ mL/hour of TPN solution 
Step VI: Determine the 
daily vitamin 
requirements  
 
Vitamin K: 0.5 mg/kg ×_____ kg = ____ mg vitamin K SQ 
given once weekly if needed 
 
Possibly supplementation with vitamin B 
For example: 
BER  ÷ 1 mL B complex/1000 kcal = ____ mL 
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Step VII: Administer the 
TPN 
Day 1 – administer 1/3 of calculated requirement 
= 1/3 (____ mL/day +  ____ mL of B vitamins/day) ÷ 24 hrs 
= _____ mL/hr 
 
Day 2 – administer 2/3 of calculated requirement 
= 2/3 (_____ mL/day + _____ mL B vitamins/day) ÷ 24 hrs 
= _______ mL/hr 
 
Day 3+  Administer the full calculated requirement plus 
____ mL B vitamins per day 
= _______ mL/day + _____ mL B vitamins/day ÷ 24 hrs 
= ______ mL/hr 
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Table 11.  Blank PPN worksheet 
 
Step I: Calculate the 
TER 
BER= 30 (____ kg) +70 = _____ kcal/day 
 
TER= BER × illness factor = ______ kcal/day 
Step II: Calculate the 
PER 
PER = TER × 50% 
= ______ kcal/day × 0.50 = _____ kcal/day 
 
Step III: Determine 
calorie sources for this 
patient 
 
Determine relative amounts of amino acids, dextrose and lipids 
supplied per day 
 
TER  × proportion of dextrose  = ______ kcal/day dextrose 
TER  × proportion of amino acids = ____ kcal/day amino acids 
TER  × proportions of lipid  = ______ kcal/day lipid 
 
 
Step IV: Determine the 
volume of nutrient 
solutions required –  
Dextrose 
_____  kcal/day ÷ 0.17 kcal/mL of 5% dextrose 
= _____ mL/day of 5% dextrose 
  
  
Lipids 
____ kcal/day ÷ 2 kcal/mL of 20% lipid solution 
= ____ mL/day of 20% lipid solution  
 
 
Amino Acids 
____ kcal/day ÷ 0.34 kcal/mL of 8.5% amino acid solution 
= _____ mL/day of amino acids  
         
Step V: Determine the 
total volume and hourly 
rate of PPN solution 
administration 
 
mL dextrose + mL lipids + mL amino acids = ____ mL/day of 
PPN solution 
 
_____ mL/day ÷ 24 hours = ____ mL/hour of PPN solution 
Step VI: Determine the 
daily vitamin 
requirements  
 
Vitamin K: may or may not be needed  
 
Vitamin B: possibly consider supplementing vitamin B 
 
PER ÷ 1 mL B complex/1000 kcal = ____ mL/ day  
 
 
Step VII: Administer the 
PPN 
Give at full calculated rate immediately 
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Table 12—Mean ± SD and median (range) values of lipid particle diameter 
(determined via TEM examination at 0, 24, 48, 72, and 96 hours after 
preparation) in bags of PN admixture exposed to various conditions of 
temperature and handling (5 groups of 3 bags).  
 
   Particle diameter (μm) 
Group* Time point (h) 
No. of 
particles Mean ± SD Median (range) 
     
1 0 487 0.26 ± 0.12 0.24 (0.11–1.109) 
 24 771 0.24 ± 0.09 0.22 (0.02–0.804) 
 48 1,145 0.24 ± 0.10 0.21 (0.08–1.012) 
 72 381 0.27 ± 0.13 0.24 (0.01–0.848) 
 96 1,275 0.25 ± 0.10 0.25 (0.11–0.839) 
     
2 0 912 0.25 ± 0.11 0.23 (0.01–1.03) 
 24 542 0.26±0.41 0.23 (0.11–1.12) 
 48 811 0.24±0.01 0.22 (0.08–0.73) 
 72 768 0.23±0.01 0.21 (0.01–0.96) 
 96 1,787 0.16±0.09 0.21 (0.11–1.07) 
     
3 0 459 0.26 ± 0.12 0.23 (0.01–1.08) 
 24 1,386 0.25 ± 0.11 0.23 (0.01–1.15) 
 48 1,083 0.24 ± 0.11 0.22 (0.01–1.00) 
 72 500 0.24 ± 0.11 0.21 (0.01–0.92) 
 96 549 0.26 ± 0.11 0.24 (0.10–0.82) 
     
4 0 391 0.25 ± 0.10 0.24 (0.02–1.053) 
 24 1,516 0.24 ± 0.10 0.23 (0.01–0.981) 
 48 784 0.23 ± 0.09 0.24 (0.08–0.702) 
 72 382 0.25 ± 0.11 0.24 (0.01–0.706) 
 96 560 0.27 ± 0.11 0.25 (0.11–1.424) 
     
5 0 959 0.27 ± 0.13 0.23 (0.11–1.50) 
 24 2,017 0.25 ± 0.10 0.28 (0.02–0.96) 
 48 782 0.25 ± 0.12 0.22 (0.11–0.84) 
 72 782 0.27 ± 0.12 0.23 (0.11–0.84) 
 96 716 0.29 ± 0.15 0.17 (0.11–0.93) 
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*Bags of PN admixture were exposed to various experimental conditions; during the 
exposures, admixture samples were emptied from each bag via an IV fluid administration 
set to mimic administration to a patient. For 96 hours, three bags of PN admixture were 
kept in a static position at refrigeration temperature (4°C; group 1);  kept at room 
temperature (23°C) and continuously agitated on a test tube orbital rotating device in a 
circular motion (rotation speed, approx 360°/s [60 revolutions/min]; group 2); kept at 
room temperature and agitated intermittently on a test tube orbital rotating device in a 
circular motion (rotation speed, approx 360°/s [60 revolutions/min]) for 5 minutes every 
4 hours; (group 3); kept in a static position at room temperature (solution passed through 
a 5-μm filter placed at the approximate midpoint of the IV fluid administration set tubing; 
group 4); or kept in a static position at room temperature without further intervention 
(control; group 5).   
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Appendix 6. FIGURES 
 
Figure 1.  Strict blood glucose monitoring regimen.   
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Figure 2—Mean ± SD percentage distribution of lipid particle diameters 
(determined via TEM examination at 0, 24, 48, 72, and 96 hours after 
preparation) in bags of PN admixture that were kept static at room temperature 
(approx 23oC; control group) for 96 hours.   
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Figure 3.  Oil layer in Group 2 venoset at 72 hours (continuously agitated 
group).  Arrow indicates the oil layer 
 
 
 
 
 
 
 
Figure 4.  Oil layer in Group 2 intravenous pump cartridge at 72 hours 
(continuously agitated group). Arrow indicates the oil layer. 
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FOOTNOTES 
 
a. Elizabeth Thomovsky, University of Missouri-Columbia College of Veterinary 
Medicine, Personal communication, 2005.  
 
a. 3-in-1 mixing container, Abbott Laboratories, North Chicago, IL. 
b. 50% dextrose injection, Baxter Healthcare Corp, Deerfield, IL. 
c. Intralipid 20%, Baxter Healthcare Corp, Deerfield, IL. 
d. Aminosyn 8.5% sulfite-free crystalline amino acid solution (Na+, 78 mEq/L; Cl-, 
86 mEq/L; K+, 66 mEq/L; Mg2+, 10 mEq/L; acetate,61 mEq/L; and PO4-, 30 
mEq/L), Abbott Laboratories, North Chicago, IL.  
 
e. Vitamin B injection solution, Phoenix Pharmaceutica Inc, St. Joseph, Mo.   
f. Abbott Plum A+ infusion intravenous IV pump system, Abbott Laboratories, 
Abbott Park, Ill (used in groups 2 through 5) and Heska Vet/IV 2.2, Heska Corp, 
Fort Collins, CO (used in group 1). 
 
g. Lab-Line lab rotator (31 X 31 cm), Barnstead International Products, Dubuque, 
IA. 
 
h. Supor sterile syringe filter, Baxa Corp, Englewood, CO. 
i. Carbon support film on specimen grid on 200 mesh copper, Electron Microscopy 
Sciences, Hatfield, PA. 
 
k. TEM-JEOL 1200 EX, Japan Electron Optics Limited, Tokyo, Japan. 
l. Adobe Photoshop, version CS2, Adobe Systems Inc, San Jose, Calif. 
m. Fovea Pro 4.0, Reindeer Graphics, Asheville, NC. 
n. Microsoft Excel, Microsoft Corp, Redmond, WA. 
o.   SigmaStat, version 3.0, SPSS Inc, Chicago, IL.  
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